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CHAPTER 1 
INTRODUCTION 
1.1 Nanoparticles and cancer chemotherapy 
 Nanotechnology has great potential in the cancer therapy as it may provide enhanced 
efficacy and reduced side effects over conventional treatments such as radiation and 
chemotherapy (Farokhzad and Langer, 2009; Schroeder et al., 2012). These features are mainly 
due to the improved solubility of hydrophobic drugs (Ensign et al., 2012), ability to encapsulate 
drug combinations (Milane et al., 2011a), decreased drug resistance (Jabr-Milane et al., 2008), 
higher accumulation of drugs in tumors (SchÃ¤dlich et al., 2011) and active intracellular 
delivery of nanoparticles in the tumor cells (Panyam and Labhasetwar, 2003). Various strategies 
have been investigated to localize nanoparticles at tumor sites, including passive tumor targeting 
by Enhanced Permeation and Retention (EPR) effect (Greish, 2007; Matsumura and Maeda, 
1986) and active targeting by attaching targeting moieties that bind to receptors which are 
specifically over-expressed in cancer cells (Brigger et al., 2002). Based on these strategies, 
nanoparticles have been investigated to kill tumor cells and to spare healthy tissues but much 
success has not been accomplished yet. The main reasons for the limiting success are variable 
drug release pattern, low drug loading capacity of nanoparticles, aggregation of nanoparticles, 
which leads to increase in the uptake by reticuloendothelial (RES) system, and limitations to 
combine with other emerging therapies such as gene therapy (Brannon-Peppas, 1995; 
Dobrovolskaia et al., 2008; Schroeder et al., 2012). Different types of nanocarriers such as 
polymeric nanoparticles, micelles, liposomes and inorganic nanoparticles haven been 
investigated to address these complex problems but search for the “magic bullet” is still on 
(Farokhzad and Langer, 2009; Nasongkla et al., 2006; Schroeder et al., 2012). 
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1.2 Mesoporous Silica Nanoparticles 
 Since discovery of M415 material family by Mobil Corporation scientists in 1992 and the 
application of MCM-41 materials in the drug delivery by Vallet Regi et al. in 2000 (Vallet-Regi 
et al., 2000), mesoporous silicas have been widely investigated as a reservoir for controlled drug 
delivery and theranostics (Zhang et al., 2012), and as a platform for drug-gene combinations 
(Chen et al., 2009a). Feasibility of adjusting the pore size of nanoparticles offers a versatile 
platform for inclusion of drug molecules in the silica matrix despite of differences in their 
physicochemical properties (Lu et al., 2007a; Wani et al., 2012). Generally, polymer matrices 
have been reported as controlled drug delivery systems which encapsulate drugs (Farokhzad and 
Langer, 2009) as well as act as a crystallization inhibitor for guest molecules (Panyam et al., 
2004). Heterogeneous distribution of drug molecules in the polymeric matrix affects the release 
rate between different samples (Huang and Brazel, 2001). Materials with homogenous porosity 
would facilitate homogenous drug distribution and much improvement in the drug release would 
be expected (Vallet-Regi et al., 2000). Well defined, homogenous porous structure of 
mesoporous silica fulfills these parameters and presents an interesting alternative for the 
polymeric devices.  
Mesoporous silica offers high surface area, easy surface functionalization, high drug 
loading capacity, compatibility with hydrophilic as well as hydrophobic drug molecules, 
amorphization of pharmaceuticals and high biocompatibility all of which may play an important 
role in the oral as well as injectable formulations (Bhattarai et al., 2010; Meng et al., 2011a; Qian 
and Bogner, 2011). In this section, I will present a current status of mesoporous silica 
nanoparticles (MSN) as oral and injectable drug delivery systems.  
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1.2.1 Current status of MSN in drug delivery 
1.2.1.1 MSN as oral drug delivery systems 
Oral administration of drugs is simplest, easiest and most common route of 
administration. During absorption of drugs from GI tract, drug molecules enter into liver via 
portal circulation called “First Pass”. During this process, drugs may be metabolized in the liver 
before being bioavailable and hence, first pass metabolism is the biggest challenge and 
disadvantage of oral drug delivery. However, not all drugs are orally bioavailable. This includes 
poorly soluble drugs, large molecules, highly charged compounds or drugs susceptible to 
degradation by stomach acid or various enzymes in the GI tract. Formulation development 
strategies play an important role in facilitating absorption of such molecules from the GI tract 
(Ensign et al., 2012). Rate of dissolution is a rate-limiting step for poorly soluble class II drugs 
(Biopharmaceutical Classification System) and selection of physical form (crystalline or 
amorphous) of drug candidate by solid-state characterization is important for oral bioavailability 
(Panyam et al., 2004; Takano et al., 2008). In general, amorphous drugs are thermodynamically 
unstable, especially in the presence of water, with decrease in the glass transition temperature 
(Tg), transformation of amorphous-to-crystalline form have been widely reported (Qian and 
Bogner, 2011; Yu, 2001). Because of the above mentioned issues, amorphous forms are rarely 
chosen for the development of solid dosage forms. However, polymorphs (different crystal 
structure but the same chemical composition) create profound implications on formulation 
development with significantly different solubility, dissolution rate, compactibility, 
hygroscopicity, physical and chemical stability (Kawakami, 2012). Polymorph that gives higher 
solubility and faster dissolution rate is usually a preferred candidate for oral delivery. However, 
it is worth noting that polymorph with the high solubility and faster dissolution rate is also a 
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metastable (i.e. high-energy form) and conversion of metastable to thermodynamically more 
stable polymorph is often possible, resulting in lower oral bioavailability. For example, in the 
case of ritonavir, an antiretroviral agent, the most stable form appeared after two years after 
launch of the product due to conformational polymorphism which resulted in formation of 
polymorph with distinct differences in the solubility pattern and threatened sale of the product 
(Bauer et al., 2001; Kawakami, 2012). Therefore, companies prefer to select most 
thermodynamically stable polymorph for formulation development. 
Various strategies such as salts, prodrugs, particle size reduction, solubilizing excipients, 
microemulsions, co-solvents and cyclodextrin-based inclusion complexes have been widely 
investigated to increase solubility and dissolution rate to achieve satisfactory absorption and 
bioavailability (Davis and Brewster, 2004; Kawakami, 2012). Amorphization (crystalline-to-
amorphous transformation) of active pharmaceutical ingredients (API) is an actively pursued 
area of research. Ordered structure of a crystal may be disrupted by solid dispersion, 
supercooling, dehydration, milling, and annealing of metastable crystalline forms (Kawakami, 
2012; Qian and Bogner, 2011; Willart and Descamps, 2008). As mentioned above, such 
amorphous forms are present in the higher energy state and spontaneous re-crystallization over 
time might negate the solubility advantage. However, formulators should take care in selecting 
such amorphization technique to achieve required physical and chemical stabilities from the 
therapeutic standpoint. Out of the above-mentioned approaches, solid dispersion has been proved 
to be the most successful in enhancing dissolution profile and solubility (Panyam et al., 2004; 
Qian and Bogner, 2011).  In general, solid dispersion technology can be classified into eutectic 
mixtures, solid solutions and physical mixture of microcrystalline drug dispersed in the 
polymeric carrier. When drug is molecularly dispersed in polymer, driving force for drug 
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crystallization is reduced and polymers kinetically act as a crystallization inhibitor by lowering 
the mobility of drug molecules. Widely used solid dispersion agents are polyethylene glycol 
(PEG), polyvinylpyrrolidone (PVP), sugars, and urea. It is generally believed that solid 
dispersions can enhance the dissolution rate through one or combination of the following factors: 
(a) Increasing surface area: a drug exists as fine crystalline particles in a solid dispersion, 
which drastically increases surface area of the drug compared to conventional 
formulation 
(b) Surface modification through intimate contact with hydrophilic carrier: when eutectic 
mixture or physical mixture is formed, surface properties of drug molecules are 
modified with hydrophilic polymer such that it wets surface more easily. 
(c) Increased solubility through formation of solid solution: In case of solid solution, 
hydrophilic carrier molecules are replaced with drug molecules or interstitial 
positioning of drug molecules in the polymer carrier lattice to form a one phase 
system. Such drug forms a molecular dispersion and is present in a molecular state 
called as a “solid solution” the step of drug dissolution is bypassed. 
Disadvantage of solid dispersion strategies are mainly related to their physical stability 
(Serajuddin, 1999). Physical treatments such as pulverization and ageing may destabilize the 
system and changes can occur in the crystalline profile and a dissolution rate. Moisture 
absorption and temperature are critical factors in destabilizing high-energy, metastable forms, 
causing phase separation, crystal growth or conversion to stable crystalline form during storage, 
which may result in variable oral bioavailability. Selection of material which will give single 
phase system with drug molecules that will remain miscible with the material is important for 
long-term physical stability and there is a need for thermally and chemically stable material 
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which will act as an amorphization platform for poorly soluble class II drugs (Qian and Bogner, 
2011).  
 Mesoporous silica offers large surface area (e.g. greater than 500 m2/g), well ordered 
porous structure, high pore volume (approximately 1 cm3/g), high mechanical strength, thermal 
and chemical stability, and resistance to microbial attack as compared to their polymeric 
counterparts (Bhattarai et al., 2010; Qian and Bogner, 2011; Rosenholm et al., 2010b). Large 
surface area allows adsorption of drug molecules into nanosized capillaries, thus decreasing 
overall Gibbs free energy and stabilizing the system at a lower free energy state. The adsorbed 
molecules are present in the amorphous form in the silica matrix because the silica matrix 
prevents crystal growth and nucleation due to the pore size-constraint effect. Amorphous porous 
silica system will crystallize only when thermodynamic states of the system are perturbed 
(Martens et al., 2008; Qian and Bogner, 2011). Mesoporous silica is thus an interesting excipient 
which may act as a crystallization inhibitor as well as a conventional glidant to improve flow 
properties, thus facilitating dual function in the development of oral dosage forms. By 
controlling surface functionalization, silica can be used in the immediate as well as controlled 
release solid dosage formulations. Efforts have been made to improve oral bioavailability of 
itaconazole, a triazole antimycotic compound, which has low aqueous solubility (less than 1 
ng/ml at pH = 7) (Mellaerts et al., 2008b). Mellaerts and co-workers prepared solid dispersion of 
itraconazole using mesoporous silica and found that molecularly dispersed itraconzaole was 
present in the amorphous form, which was confirmed by the absence of Tm and Tg in the tested 
formulation. Dissolution studies of the mesoporous silica-based intraconazole formulation 
showed higher solubility of the amorphous formulation when compared with pure crystalline 
itraconazole (Mellaerts et al., 2007). Based on the similar principle, solubility improvement was 
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observed for wide range of compounds when formulated with porous silicas, including 
carbamazepine (Thomas et al., 2010), carvedilol (Hu et al., 2012), diazepam, indomethacin, 
grisofulvin, ketoconazole (Van Speybroeck et al., 2009), ibuprofen (Martens et al., 2008), 
nifedipine and telmisartan (Zhang et al., 2010a).  The unique phase transformation of drugs in 
the presence of mesoporous materials can be advantageous in formulating and delivering poorly 
soluble class II drugs to improve oral bioavailability. MSN-based solid dispersion is a potential 
way to solve stability-related problems and a suitable alternative to polymer-based solid 
dispersion technique. More work is needed to elucidate detailed mechanism of amorphization 
and to promote the use of MSN in oral delivery systems. 
1.2.1.2 MSN as injectable delivery systems 
Another important aspect of mesoporous silicas is their potential as a colloidally-stable 
injectable formulation because of the easy surface functionalization, biocompatibility, controlled 
rate of degradation, and control over particle size and shape during synthesis (Bhattarai et al., 
2010; Chen et al., 2009a; Rosenholm et al., 2010b). Generally, particles below 200 nm are 
suitable for intravenous administration and simple but robust method of MSN synthesis 
facilitates desired particle size with homogenous porous structure. Suitable properties of 
injectable nanoparticle formulations include limited aggregation, long circulation time, 
biodegradability, absence of dose dumping, and ability to home to the targeted site (Farokhzad 
and Langer, 2009; Schroeder et al., 2012). An optimal delivery system for effective anticancer 
therapy should be able to reach desired tumor site with minimal loss of activity while in the 
circulation. After reaching the tumor tissue, particles should enable a controlled delivery of cargo 
in the active form. Surface functionalization of MSN with PEG and tumor targeting ligands may 
have the potential to satisfy the above-mentioned requirements.  
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 Nanoparticles without surface modification are usually rapidly cleared from the 
circulation by RES based on the nanoparticles size and surface properties such as charge, and 
hydrophobicity (Fox et al., 2009). The fate of systemically administered particles can be 
controlled by adjusting particle size, particle shape and surface functionalization (Yu et al., 
2012). Nanoparticles can be surface functionalized to achieve passive or active targeting by 
controlling size of the nanoparticles or by attaching targeting ligands (Rosenholm et al., 2010b; 
Schroeder et al., 2012). Incorporation of PEG also enables passive targeting to tumors via EPR 
effect (van Vlerken et al., 2007). PEG is a hydrophilic polymer, which helps to reduce charge on 
the particles and provides “stealth” coating for camouflaging particles from macrophages. On 
this topic, Nel and co-workers investigated effect of particle size reduction and polymer coating 
of MSN on passive accumulation in KB-31 luc xenograft model and reported enhanced rate of 
tumor shrinking with doxorubicin loaded MSN compared to free doxorubicin (Meng et al., 
2011a). On the same note, passive targeting can also be achieved by controlling shape of the 
nanoparticles. Ghandehari and co-workers reported that rod-shaped gold nanoparticles 
accumulate at higher concentration in the tumor compared to spherical shaped gold nanoparticles 
which may be due to less recognition by macrophages, increase in the circulation time and higher 
tumor cell uptake (Arnida et al., 2011).  
Active targeting can be achieved by conjugating targeting antibodies, peptides, aptamers 
and ligands overexpressed on cancer cells to the surface of nanoparticles (Rosenholm et al., 
2010b). Surface functionalized nanoparticles can overcome P-gp- mediated drug resistance by 
avoiding recognition by P-gp because being enveloped in an endosome when entering cell, 
leading to higher intracellular drug concentration (Chavanpatil et al., 2006). Zink and co-workers 
functionalized camptothecin loaded MSN with folate and observed enhanced cytotoxicity with 
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about 60% cell death after 24 h for PANC 1 cells, however, non-targeted particles showed 
cytotoxicity of about 30% after 24 h (Liong et al., 2008). Successful active targeting of MSN 
was also reported by Rosenholm et al. who conjugated anti-cancer drug, methotrexate, which is 
structurally similar to folate, on the surface of MSN. In this way, methotrexate was able to act 
dually as a targeting ligand as well as a chemotherapeutic agent. They observed that 
methotrexate-MSN induced apoptotic cell death in cancerous HeLa cells while significantly less 
apoptosis was observed with the non-cancerous HEK-293 cells at the similar biological 
concentrations (Rosenholm et al., 2010a). The same authors also reported that the level of cancer 
cell apoptosis induced by MSN conjugated with methotrexate was significantly higher than the 
corresponding concentration of free methotrexate. Overall, mesoporous silica materials satisfy 
many of the pre-requisites for passive and active targeting mechanisms in tumor delivery. 
MSN has been extensively investigated for controlled release of anti-cancer drugs (Li et 
al., 2010; Lu et al., 2007a; Meng et al., 2011a; Meng et al., 2010a; Wani et al., 2012), DNA 
(Bhattarai et al., 2010), siRNA (Chen et al., 2009a) as well as proteins (Lin et al., 2008). 
Controlled release was achieved by modifying MSN with various stimuli responsive barriers 
which protect the cargo from unwanted leakage during circulation but allow release of the 
content in response to specific stimulus at the targeted site. Effects of stimulus such as pH, 
temperature and redox gradient on controlled drug release have been widely studied (Bhattarai et 
al., 2010; Singh et al., 2011). Table 1 shows examples of such strategies capable of controlling 
release of guest molecules. Reliable controlled release of loaded cargo at physiological condition 
is a challenging endeavor and care should be taken in selecting the stimulus for particular 
application and disease condition. Though most of the below mentioned strategies worked in 
vitro, less effort has been invested in extrapolating these strategies towards preclinical setting. 
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Singh et al. reported that increase in the release of doxorubicin in response to proteases present at 
the tumor site in vivo and showed higher cellular apoptosis signifying importance of stimuli 
responsive delivery (Singh et al., 2011). 
Table 1. Strategies capable of controlling release of guest molecules from MSN by specific 
stimulus  
Stimulus Capping barrier Cargo Application Reference 
Temperature PNIPAM Doxorubicin Human sarcoma (Singh et al., 2011) 
Redox (DTT)  poly(2-diethylamino) 
ethyl methacrylate)   Rhodamine B N.A. 
(Kotsuchibashi 
et al., 2012) 
pH Chitosan Ibuprofen N.A. (Popat et al., 2012) 
Magnetic Fe3O4 Fluorescein N.A. 
(Giri et al., 
2005) 
Redox (GSH) β-cyclodextrin Doxorubicin Adenocarcinoma (Kim et al., 2010) 
pH PDMAEMA Chloroquine Breast cancer (Bhattarai et al., 2010) 
pH 
Polyethyleneimine/β-
cyclodextrin 
polyseudorotaxane 
Calcein N.A. (Park et al., 2007) 
Protease PNIPAM-co-PEG Doxorubicin Human sarcoma (Singh et al., 2011) 
Redox (H2O2) IgG Metal 
chelator Alzheimer 
(Geng et al., 
2012) 
Ultrasound Chitosan Ibuprofen N.A. (Depan et al., 2010) 
N.A.  Application is not reported 
  Polypseudorotaxane formation between cyclodextrin (CD) and PEI-b-PEG-b-PEI 
polymer undergoes selective complexation and decomplexation between CD and PEI as a 
function of pH. It served as a template for MSN to control the release of loaded cargo (Park et 
al., 2007). Calcein, a fluorescent molecule, was encapsulated into CD-MSN and controlled 
release of calcein as a function of pH was reported. Validity of such sophisticated mechanism 
needs to be verified with biologically important molecules in in vitro as well as in vivo settings. 
11 
 
 
Table 1 confirms that easy surface functionalization makes MSN a suitable platform to develop 
as a stimuli-responsive delivery system.  To take advantage of this promising delivery system, it 
is necessary to focus on the physicochemical parameters of MSN that controls drug loading, drug 
release and overall biological outcome.  
1.2.2  Physicochemical aspects of MSN 
 The ultimate goal of nanoparticles in anti-cancer therapy is to improve killing of cancer 
cells and to spare non-cancerous or healthy cells and tissues. To achieve such efficient targeted 
therapy, it is important to understand how physicochemical aspects of MSN such as particle 
synthesis, particle size, particle shape, surface functionalization, hydrolytic stability, 
redispersibility affect biological outcome.   
1.2.2.1 Particle synthesis  
In case of MSN, the particle size range of interest for targeted intracellular delivery is 
about 50-200 nm as large particles can be excreted out by immune systems and smaller particles 
are too difficult to synthesize as a consequence of inherent mesoporosity. Monodisperse particles 
are also preferred as it allows uniform biodistribution and homogenous release profile in the 
body (Farokhzad and Langer, 2009; Schroeder et al., 2012; Xie and Smith, 2010). Therefore, 
chemical synthesis methods have been widely used to prepare mesoporous silicas as opposed  to 
physical methods such as spray-drying which results in large particles with wide particle size 
distribution (Rosenholm et al., 2010b). In most synthesis procedures, tetraethoxysilane (TEOS) 
has been used as a silica precursor. Cetyl trimethyl ammonium bromide (CTAB), a cationic 
ammonium salt, has been used as a structure-directing agent (Bhattarai et al., 2010; Giri et al., 
2005). This sol-gel synthesis often referred as Stöber method leads to particles with pore size of 
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2-4 nm and cylindrical mesostructure arranged in a hexagonal fashion. Simple MSN synthesis 
also allows incorporation of functional groups by reacting respective functional silanes with the 
silica precursor. Selection of pore size of MSN depends upon the size of encapsulated cargo. 
Considering loading of anti-cancer small molecules, pore size of 2-4 nm is sufficient, however, 
recently efforts have been made in increasing pore size of MSN to accommodate 
macromolecules such as DNA and proteins (Gao et al., 2009; Slowing et al., 2007). Pore size 
modification can be easily achieved by the addition of pore swelling agent, trimethylbenzene 
(TMB), during condensation. However, care should be taken in such a way that TMB is 
preferentially solubilize in alcoholic solvent rather than encapsulated in micellar surfactant to 
achieve desired pore size (Rosenholm et al., 2010b; Slowing et al., 2007). The largest pore size 
for MSN is reported to be 20 nm (Gao et al., 2009). In this case, MSN was synthesized in acidic 
condition rather than alkaline condition with polymeric ABA block copolymer surfactant as the 
structure-directing agent.  However, particle size distribution for these MSN are broader 
compared to MSN synthesized by alkaline condition. 
 A key important step in obtaining well-dispersed nanoparticles is the removal of 
surfactant template. Template removal is normally performed by acid hydrolysis, as thermal 
decomposition leads to the loss of surface functional groups present on the mesoporous structure. 
MSN obtained with thermal decomposition process also lead to inter-particle condensation and 
may increase the overall particle size distribution. It is worth noting that care should be taken in 
removal of CTAB completely as CTAB is cytotoxic and may hampered use to such system in the 
biological condition. Shi and co-workers recently reported a modified method of MSN synthesis 
to achieve highly dispersed particles with particle size as low as 25 nm with excellent colloidal 
stability (Pan et al., 2012). They incorporated hexadecyl trimetyl ammonium chloride (CTAC) as 
13 
 
 
a structure directing agent in a silica precursor. Size of the nanoparticles was controlled by 
addition of triethanolamine (TEA), with lower TEA content (0.02g) giving larger MSN (105 nm) 
while higher TEA content (0.08g) giving smaller particle size of 25 nm. However, surface area 
of particles decreased from 561 to 391 cm2/g with decrease in the particle size from 105 nm to 25 
nm. Similarly, Lin and co-workers reported a synthesis of rod shaped mesoporous silica 
nanoparticles by modifying conventional MSN synthesis and its application in controlled drug 
delivery confirming flexibility of material in obtaining desired particle size and shape (Giri et al., 
2005). At the same time, surface modification of the mesoporous channels and/or external 
particle surfaces with various functional groups also gives more temporal control over 
manipulation of surface properties for controlled drug delivery and biomedical applications 
(Bhattarai et al., 2010; Giri et al., 2005; Rosenholm et al., 2010b; Slowing et al., 2007; Wani et 
al., 2012). 
1.2.2.2 MSN hydrolytic stability 
Another important aspect of nanoparticles used in drug delivery is their chemical stability 
in endogenous conditions. Particle dissolution profile is important to determine as it controls (i) 
drug release and (ii) overall drug circulation time in vivo. From toxicological point of view, it is 
important to understand degradation profile of MSN in aqueous conditions as it may help to 
elucidate long-term toxicity associated with nanoparticle accumulation. However, it is quite 
surprising that limited number of systematic studies have focused on the dissolution profile of 
MSN in the biological environment. Generally, exterior surface of MSN contains functional 
groups, targeting ligands and protective polymeric layers and it is necessary to understand MSN 
dissolution rate as faster degradation of particles may dissociate surface functionalities prior it 
reaches targeted site. Furthermore, hydrolytic stability is important for the Active Pharmaceutical 
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Ingredient (API) physical state as faster degradation of nanoparticles may change amorphization 
profile of the API due to the changes in the mesoporous structure. Walcarious et al. investigated 
dissolution profile of unmodified and amino- functionalized silica at different pH (Etienne and 
Walcarius, 2003). They found that amino-modified MSN dissolved at a faster rate than 
conventional silica under simulated biological conditions. The same group also reported that 
amine group dissociation reached plateau after 4 h indicating not all surface functionalities are 
dissociated from particles and signifies role of surface charge in increasing the rate of 
dissolution. Onida and co-workers investigated dissolution profile of mesoporous silica with 
particle size ranging from 200 to 800 nm in the simulated body fluid (Mortera et al., 2010). They 
found a rapid decrease in the mesopore volume during the first hour of incubation, while XRD 
confirmed the presence of mesoporous structure in the particles. Authors concluded that the 
dissolved silica re-deposited on the porous opening gradually closing the pores. Authors 
supported their claim by drug release measurements, where the drug release rate attained plateau 
at the same time when mesoporous volume was strongly diminished. Similarly, He et al. reported 
a three stage degradation behavior of MSN in simulated body fluid (Scheme 1) (He et al., 
2010a). This study revealed rapid initial bulk degradation, followed by the deposition of 
calcium/magnesium silicate layer which drastically decreased the degradation rate. The third 
Scheme 1. Schematic illustration of the degradation profile of mesoporous silica in SBF 
proposed by He et al. The initial fast bulk degradation is retarded by the formation of Ca/Mg-
silicate layer (stage 2) followed by a slow diffusion-controlled degradation behavior over 
several days (stage 3). Adapted from (He et al., 2010a). 
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stage involved a maintained slow diffusion of dissolved silica species, while the whole sample 
was degraded after 15 days of incubation. Interestingly, particle morphology remained intact 
after 24 h, even though etching and enlargement of pores was clearly observed. On the same 
note, Oupický and co-workers also observed degradation of silica with intact particle 
morphology after 24 h of incubation in biologically relevant media (Bhattarai et al., 2010). The 
hydrolysis of particles as a function of particle size under in vivo condition is important to 
understand as small particles may disintegrate faster than larger particles and this may affect 
clearance mechanism for different particle size silica. These results clearly highlight the need for 
detailed particle disintegration studies in relation to drug delivery application of MSN.  
1.2.2.3 Drug loading 
Large surface area, tunable pore size and pore volume make mesoporous silica an ideal 
candidate to load large amount of drug molecules in the porous structure. Based on the available 
literature, drug loading procedures can be classified as: (i) adsorption from solution, (ii) incipient 
wetness impregnation and (iii) melting of mixture of drug and mesoporous silica (Mellaerts et 
al., 2008a). MSN are suitable for hydrophilic as well as hydrophobic compounds and based on 
API solubility, drug-loading process can be performed in the organic solvent or water. Selection 
of loading method generally depends on the availability of API, its solubility profile and 
physicochemical properties. 
 In adsorption from solution method, slurry of API is usually stirred in presence of porous 
material to allow drug adsorption, followed by centrifugation or filtration to separate drug-loaded 
particles from solution. Although this is a widely used method, adsorption of drug molecules, in 
fact, is a low yielding process. Generally, drug molecules adsorb in a monolayer fashion which 
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can be modeled using Langmuir adsoprtion isotherm (Qian and Bogner, 2011; Rosenholm et al., 
2010b). This is because after the first monolayer on the silica surface, succeeding drug layers are 
associated more closely with the solvent. Similarly, monolayer formation was also observed 
during protein adsorption from aqueous solutions (Vinu et al., 2004). For hydrophilic drugs, 
adjustment of pH is required to yield high drug loading levels than what is possible from organic 
media (Ma et al., 2011; Salonen et al., 2005). Zink and co-workers studied the effect of pH on 
loading of doxorubicin and found that higher loading was observed at neutral than at acidic pH 
(Meng et al., 2010a). Many studies have highlighted the possibility of using adsorption from 
solution method for hydrophilic as well as hydrophobic drugs (Bhattarai et al., 2010; Li et al., 
2010; Liu et al., 2012; Meng et al., 2011a; Wani et al., 2012).  
In incipient wetness method, measured concentration of drug solution is generally added 
into mesoporous silica to achieve sufficient surface wetting and solvent is evaporated at elevated 
temperature (Mellaerts et al., 2008a; Qian and Bogner, 2011). This method gives more control 
over drug loading as different concentrations of drug solution may be prepared to control drug 
loading degree based on the need of the specific application. Solubility of drug molecule in the 
selected solvent may limit the loading efficiency of this method. As incipient wetness allows 
direct control over the amount of drug to be transferred from solution to porous silica, it may 
compromise amorphization of drug molecules based on the rate of evaporation. There is a need 
to study the effect of speed of evaporation on solid state of the loaded molecules. In both of the 
above-mentioned methods, selection of solvent is very important as it contributes to the 
efficiency of drug loading. 
The third method, heating or melting method, involves heating of drug-silica mixture up 
to the melting point of drug molecules allowing drug to enter into porous nano-confinement. 
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However, melted drugs often adsorb on the exterior surface of MSN, blocking access to the 
porous structure. Martens and co-worker loaded intraconazole by melt method and found that 
mesoporous volume, total pore volume and mesopore size was similar to that of the empty 
particle indicating melt method has little effect on porosity (Martens et al., 2008). They speculate 
that high viscosity of molten intraconazole may impede the flow of liquid into the pores. In 
addition, heating of mixture may lead to decomposition of the drug and functional groups in  
MSN, hence  the melting method is less applicable in drug loading for MSN.  
1.2.2.4 MSN formulation 
In this section, development of MSN formulations of small molecules is first discussed, 
followed by the colloidal stability approaches and drug release mechanism. Selection of MSN 
properties strictly depends upon the physicochemical properties of API. Formulators should 
follow the following steps in developing MSN formulations: 
(1) Determine physicochemical properties of API such as pKa, log P, molecular weight 
and molecular size. 
(2) Determine solubility of API. For hydrophilic compounds, effect of pH on solubility 
should be determined. 
(3) Select pore size,  surface functionalization, based on physicochemical properties of 
API 
(4) Route of administration (rod shape particle may be useful for improvement in the 
total blood circulation time) and the specific need of the application (PEGylation, 
polymer modification, attachment of targeted moiety and imaging agent) 
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(5)  Selection of drug loading method based on physicochemical properties and solubility 
profile of API 
(6) Loading of drug molecules into MSN 
(7) Investigate the effect of pre and post-surface modifications such as PEGylation, 
polymer attachment on drug loading 
(8) Determination of loading of MSN by HPLC and TGA  
(9) Characterization of drug-loaded MSN by DLS, DSC, PXRD, TEM 
The above mentioned steps are summarized in Scheme 2.  
 
 
 
 
 
 
 
The aggregation of unmodified MSN in solution leads to erroneous in vivo profile. The 
aggregates or particles with sizes above ~200 nm in diameter are readily bound with opsonin 
proteins and cleared by liver and spleen decreasing concentration of drug in the blood 
compartment. Opsonin proteins are more likely to bind to hydrophobic or charged particles than 
MSN based oral formulation
Selection of Drug molecule
Hydrophilic Hydrophobic
Drug 
loading 
Parameters
MSN Properties
Selection of Particle size
• Pore size
• Surface area
• Pore volume
• Surface functionality
• pH of aqueous solvent
• Polarity of solvent 
• Drug solubility
Selection of 
Particle shape
• Rods
• Spheres
Colloidal Stability
Steric
Stabilization
Electrostatic
Stabilization
PEGylation
• Optimization of pre- and post-PEGylation
• PEG density
• PEG architecture
• Effect of PEGylation on drug loading and release
Surface functionlization
• phosphonate groups
MSN based Injectable Formulation 
Scheme 2. Schematic representation of development of MSN based injectable formulation 
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hydrophilic or neutral particles, which accelerates rate of elimination by liver and spleen 
(Farokhzad and Langer, 2009; Fox et al., 2009). On this topic, it is necessary to develop long-
circulating, colloidally stable particles to take full advantage of particulate delivery system. 
Colloidal particles are generally stabilized by electrostatic or steric stabilization. If attractive 
forces such as Van der Waals forces prevail over repulsive forces such as electrostatic forces, 
particle aggregate in clusters. Aqueous suspensions are widely stabilized by electrostatic 
stabilization, achieved by the repulsion of equally charged particles. It is considered that 
electrostatic stabilization results from the formation of electric double layer on the particle 
surface and is a function of pH and the ionic strength of the solution. The strength of repulsive 
forces decreases with the increase in the distance between particles. In this case, determination of 
isoelectric point of nanoparticles is important as at this pH the net particle charge is zero. It is 
considered that aqueous suspensions with absolute values of zeta potential above 30 mV are 
physically stabilized by electrostatic stabilization. In case of MSN, presence of high surface 
concentration of silanol groups can lead to formation of siloxane bridges between the particles 
making colloidal stability a challenge (Rosenholm et al., 2010b). Phosphonate modification of 
MSN can overcome the aggregation, making the particles more dispersible (Lu et al., 2007a). On 
the same note, it is reported that amino-functionalized MSN have higher redispersibility 
compared to thiol-modified MSN, suggesting importance in the selection of surface functionality 
(Rosenholm et al., 2010b). Polymer modification of MSN by cationic polymers such as PEI also 
leads to higher zeta potential making particles more electrostatically stable (Bergman et al., 
2008). Under in vivo condition, electrostatic stabilization is less efficient due to the adsorption of 
proteins on the charged particle surface which makes particles more recognizable to the immune 
system.  
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Steric stabilization is another approach of achieving highly stable aqueous suspensions by 
adsorption or covalent attachment of polymers to the surface of MSN. In steric stabilization, 
polymer chains prevent particles to get close in the range of attractive Van der Waals forces. 
Hydrophilic polymers such as PEG have been widely used to stabilize particles by steric 
stabilization. Sometimes particles are stabilized by electrostatic as well as steric stabilization 
which is called electrosteric stabilization. Ya et al. reported that increase in the molecular weight 
of chitosan increases the thickness of chitosan layer attached to poly(butyl cyanoacrylate) 
nanoparticles which resulted in an increase in the steric repulsive energy and the electrostatic 
repulsive energy, and increased the potential energy between the two particles (Yang et al., 
2000). The electrosteric principle has been reported for dextran-modified nanoparticles as well as 
other polymeric surfactants (Douglas et al., 1985). Effect of polymeric layer on drug loading and 
release has to be examined when aiming for sterically stabilized mesoporous silica.  
1.2.3  Cellular aspects of MSN 
1.2.3.1 Cell uptake 
Studies of the interactions between inorganic nanoparticles and mammalian cells have 
shown great potential in using these materials in various biomedical applications such as drug 
and gene delivery (Chen et al., 2009a), disease diagnosis (Brigger et al., 2002), cell type 
recognition and imaging (Slowing et al., 2007). The physicochemical properties such as surface 
chemistry, particle size, and particle shape of MSN play key roles in determining biological 
behavior of the particles, and these critical parameters need to be considered when developing 
MSN for targeted drug delivery. The uptake of nonfunctionalized, negatively charged MSN by 
cells has been found to occur through non-specific adsorptive endocytosis. Lin and co-workers 
investigated effect of surface functionalities on uptake of MSN in HeLa cells and found higher 
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cell uptake for FITC and aminopropyl-functionalized MSN than for guanidinopropyl and folate- 
aminopropyl-functionalized MSN (Slowing et al., 2006a). They reported that FITC and 
aminopropyl-MSN had higher endosomal escape compared to other functionalized particles. 
Interestingly, aspect ratio which controls shape of the particles has shown to limit the rate of cell 
uptake (high aspect ratio = high and fast cell uptake) (Huang et al., 2010). Nel and co-workers 
recently investigated the effect of MSN aspect ratio MSN on HeLa cell uptake and found that rod 
shaped particles showed higher cell uptake through micropinocytosis compared to spherical 
MSN (Meng et al., 2011b). Such accumulating results suggest that spherical nanocarriers may 
not be the optimal delivery system due to poor cell uptake and unsatisfactory biodistribution 
compared to particles with higher aspect ratios (Arnida et al., 2011). Available evidences suggest 
that optimization of the shape of nanoparticles is essential to achieve long circulating 
nanocarriers after intra venous administration. 
1.2.3.2 Cytotoxicity 
In vitro toxicity studies are often using as preliminary screening process before 
determining safety of biomaterial in vivo. Parameters such as surface chemistry, particle size, 
charge and particle shape affects particle aggregation, protein adsorption on particles, interaction 
at the cell-particle interfaces and intracellular particle trafficking are all critical determinants of 
cellular toxicity and in vivo behavior (Rosenholm et al., 2010b; SchÃ¤dlich et al., 2011; Slowing 
et al., 2006a). Toxicity studies based on these parameters have indeed been reported for 
mesoporous silica to some extent but more extensively for non-porous silica. The studies 
demonstrated size dependent toxicity of silica nanoparticles on endothelial cells (Napierska et al., 
2009). Particles above 100 nm showed very little toxicity while sub-50 nm particles induced 
greater cell death. Dosage of particles is a critical determinant for cellular toxicity and reported 
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“safe concentration” for MSN is up to 100 µg/ml (Slowing et al., 2007; Wani et al., 2012). 
Particle toxicity is also influenced by surface charge. It has been demonstrated that positively 
charged amino-functionalized mesoporous silica has lower cellular toxicity compared to 
negatively charged unmodified MSN in in vitro conditions (Tao et al., 2009). On the same note, 
Pasqua and co-workers reported that thiol and amino functionalized MSN induced higher cell 
death compared to unmodified mesoporous silica (Di Pasqua et al., 2008). These reports suggest 
that critical evaluation of toxicity of MSN is needed before its preclinical application.  
1.2.3.3 Intracellular delivery of drugs and genes by MSN 
The optimal intracellular delivery system should not only be endocytosed at higher rate 
but also be capable of releasing cargo efficiently at the right intracellular target. MSN is a 
versatile platform which has successfully transported hydrophobic molecules such as PTX, 
camptothecin (Lu et al., 2007a), hydrophilic drugs such as doxorubicin(Chen et al., 2009a; Singh 
et al., 2011), membrane impermeable proteins such as cytochrome (Slowing et al., 2007) and 
various genes and siRNAs (Bhattarai et al., 2010) to the intracellular environment. Intracellular 
trafficking of particles is an area of interest as it may allow monitoring of real time delivery and 
location. Based on the mode of action of the drug and the route of intracellular trafficking it may 
possible to develop optimal delivery system. Due to the difficulties in the quantifying 
intracellularly released drug, the intracellular drug release efficiency is often measured in terms 
of cell viability as a function of treatment with MSN loaded with cytotoxic drugs. However, it 
has been showed that the amount of fluorescent doxorubicin delivered to cells can be quantified 
by flow cytometry and HPLC but such methods are limited to inherent fluorescence of drug 
molecules (Chen et al., 2009a). Fluorescent tagging is a viable option to quantify and to monitor 
intracellular trafficking of nanoparticles but question of dissociation of tag from the 
23 
 
 
nanoparticles or the drug always being raised during analysis of such results. However, in vitro 
cell uptake, toxicity and intracellular trafficking studies show credibility of the delivery system 
and may help to conclude in vivo results. 
1.2.4 In vivo aspects of MSN  
In the case of cancer, the ultimate goal of the delivery system is to kill cancer cells or to 
make them more susceptible to the treatment with minimum damage to the healthy cells. 
Aggregation of nanoparticles accelerate accumulation of nanoparticles in the healthy organs, 
disruption of biological membranes and unwanted activation of immune response favoring 
critical evaluation of physicochemical parameters of nanomaterials to decrease biodistribution to 
healthy organs (Brigger et al., 2002; Farokhzad and Langer, 2009; Fox et al., 2009; Schroeder et 
al., 2012). In vivo aspects of MSN mainly involve determination of toxicological profile of the 
nanoparticles and their degradation products and its ability to act as a tool to deliver 
chemotherapeutics to the tumors. 
1.2.4.1 Biocompatibility of MSN in vivo 
Although many reports suggest low toxicity of MSN in the in vitro studies, it is important 
to assess toxicity and biocompatibility of MSN in vivo for crucial design of these nanomaterials 
for biomedical applications. Ghandehari and co-workers extensively evaluated in vivo toxicity in 
mice of MSN using particles with different geometry, size, porosity and surface charge (Arnida 
et al., 2011; Yu et al., 2012). They found that non-porous silica (bare or amino modified) had a 
high maximum tolerated dose (MTD) between 100-150 mg/kg body weight. Surprisingly 
mesoporous silica had a lower safety threshold with MTD between 30 to 65 mg/kg irrespective 
of the geometry. It has been reported that intravenous injection of MSN at a dose of 6 mg/mouse 
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(approximately 240 mg/kg) was too toxic and animal died immediately after injection (Hudson et 
al., 2008). Interestingly, toxicity of MSN was alleviated by amine surface functionalization, 
resulting in a 2-3 fold increase in the MTDs to 100-150 mg/kg (Yu et al., 2012). This study 
confirmed that surface functionalization is an important way to improve biocompatibility of 
MSN in vivo. It was observed that among animals showing adverse reactions, renal damage was 
the major adverse effect of MSN demonstrated by sharply increased blood urea nitrogen levels. 
Extensive damage to the heart and lung was observed with the non-porous Stöber nanoparticles 
(Arnida et al., 2011; Yu et al., 2012). Porosity is also an important parameter that influences 
toxicity. Mesoporous silica materials greatly reduced hemolytic activity compared to amorphous 
non-porous silica but still showed dose dependent hemolysis (Lin and Haynes, 2010; Rosenholm 
et al., 2010b; Yu et al., 2012). The hemolytic activity did not seem to be attributed to the 
effective surface charge. Thus, it was concluded that observed hemolysis was attributed to the 
strong electrostatic interaction between silanol of silica and trimethylammonium head group of 
RBC’s membrane lipid (Rosenholm et al., 2010b). PEGylation of MSN is also a favorable 
approach to prevent hemolysis and to improve blood compatibility. PEG forms a hydrophilic 
stealth layer on the particle surface preventing interaction of the silanol groups with RBC (Lin 
and Haynes, 2010).  Given the complexity of biological environment, it is important to address 
toxicological concerns early in the development of biocompatible materials. 
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CHAPTER 2 
SURFACE FUNCTIONALIZATION OF MESOPOROUS SILICA NANOPARTICLES 
CONROLS LOADING AND RELEASE BEHAVIOR OF MITOXANTRONE 
Please note that the content of this chapter was published in the Pharmaceutical Research 
(Wani et al. 2012). As the first author, I performed all the work in the paper except the 
nanoparticle synthesis (contributed by Dr. E. Mutthuswamy, the second author) and the 
characterization of mesoporous silica nanoparticles (contributed by Layan, the third author). All 
the authors agreed with including their work in this dissertation. 
2.1 Introduction 
 Therapeutic strategies based on nanoparticle drug delivery systems aim to improve the 
anti-proliferative activity of anticancer drugs by localizing them in a controlled fashion at the 
tumor site (Davis et al., 2008). Mesoporous silica nanoparticles (MSN), such as Mobile 
Composition Matter number 41 (MCM-41), are silica particles containing pores with diameters 
in the 1.5-20 nm range. MSN have been proposed as a suitable platform for biomedical 
applications, including drug and gene delivery (Chen et al., 2009b; Lu et al., 2007a; Slowing et 
al., 2008; Xia et al., 2009b). MSN offer several advantages in drug delivery over polymeric 
nanoparticles, including tunable pore size, large surface area, high drug loading capacity, ability 
to encapsulate hydrophilic as well as hydrophobic drugs, and easy surface functionalization. 
Existing evidence suggests that silica materials, including MSN, are biocompatible and 
bioresorbable (Viitala et al., 2005). Numerous studies described easy hydrolysis and dissolution 
of porous silica particles in simulated physiologic conditions (Finnie et al., 2009; Galarneau et 
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al., 2007; Lin and Haynes, 2010). The particles are typically hydrolyzed into silicic acid, which 
is known to undergo renal elimination in vivo (Jugdaohsingh et al., 2000). 
Hydrophobic polymeric nanoparticles efficiently encapsulate hydrophobic drugs but are 
usually ill suited for encapsulation of large amounts of relatively hydrophilic drugs. Available 
reports show, for example, that only about 5% of doxorubicin can be loaded in poly(lactic-co-
glycolic) acid nanoparticles (Park et al., 2009b). In addition, delivery of hydrophilic drugs by 
hydrophobic polyester nanoparticles is subject to a potentially dangerous dose-dumping. Like 
polymeric nanoparticles, MSN are able to improve solubility and achieve controlled release of 
poorly soluble hydrophobic drugs (e.g. camptothecin, PTX) (Lu et al., 2007b; Xia et al., 2009b), 
attributable to their well-defined porosities and versatile surface chemistry. MSN have also been 
successfully developed for delivery of water soluble drugs (e.g. doxorubicin.HCl) with an 
excellent drug loading capacity (~40% w/w loading) (Chen et al., 2009b; Meng et al., 2011a; 
Meng et al., 2010b). Park et al. reported that electrostatic interactions between positively charged 
doxorubicin and negatively charged porous silica nanoparticles were responsible for the 
dramatically enhanced loading (Park et al., 2009a). Controlled release of hydrophilic molecules, 
such as adenosine triphosphate has been achieved by tailoring the pore size of microporous and 
mesoporous materials (Slowing et al., 2007). In addition, studies on tuning of pore wall 
properties such as by silylation of the silica matrix to make it more hydrophobic (Qu et al., 2006) 
or amine modification to achieve positively charged surface (Munoz et al., 2003) reveal that 
release of hydrophilic drugs can be easily adjusted.  
Another important aspect of mesoporous silica is amorphization or crystalline-to-
amorphous transformation of active pharmaceutical ingredient in the porous nanoconfinement.  
Mesoporous silica exerts a strong confinement effect on drug crystallization due to its large 
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surface area (greater than 500 m2/g) with high surface free energy and higher pore volume (e.g., 
approximately 1cm3/g). The small pore size may prevent drug molecule nucleation by preventing 
the formation of supercritical nuclei beyond critical nucleus size. In addition, the strong 
adsorption and interaction of drug molecules on the surface of mesoporous silica may also hinder 
the ordering of drug molecules necessary for crystallization. It has been reported that porous 
structure has a size-constraint effect on nucleation and crystal growth (Jackson and McKenna, 
1996; Qian and Bogner, 2011). Jacson et al. investigated effect of pore size (4 to 73 nm) of 
porous adsorbent on adsorption of crystalline o-terphenyl and found that crystalline-to-
amorphous transformation while decreasing pore size with lowest pore size particles (4 nm) 
preventing crystallization completely (Jackson and McKenna, 1996).  
MTX (Figure 1) is an anthraquinone derivative that has been extensively investigated for 
the treatment of breast and prostate cancer but its clinical application has been limited due to 
severe cardiotoxicity (van Dalen et al., 2004). Solid lipid nanoparticles (Lu et al., 2006), 
liposomes (Law et al., 1996) and polyester nanoparticles (Chen et al., 2009c) have been 
investigated to improve MTX formulation but limited drug loading capacity and poorly 
controlled release hindered their utility. Electrostatic interaction of MTX with silica matrix has 
been reported very recently (Ma et al., 2011) but systematic investigation of the effect of surface 
functionalization of MSN on MTX loading and release has not yet been reported. The goal of the 
present study was to investigate the effect of surface functionalization of mesoporous silica on 
crystallization behavior of MTX with focus on optimization of surface functionality for 
achieving amorphous MTX formulations with controlled rate of release. We predicted that 
surface functionalization of MSN will serve as a simple and robust way of controlling MTX 
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delivery without the need for introducing of any complex mechanism of drug release control into 
the design of MSN.  
2.2 Materials 
 Tetraethylorthosilicate (TEOS), 3-mercaptopropyltrimethoxysilane (MPTMS), 3-
aminopropyltriethoxysilane (APTES), N-cetyltrimethylammonium bromide (CTAB), 
hydrochloric acid, and sulfuric acid were purchased from Sigma-Aldrich (St. Louis, MO). 
Mitoxantrone dihydrochloride (MTX) was purchased from SantaCruz Biotechnology Inc. (Santa 
Cruz, CA). Roswell Park Memorial Institute (RPMI), phosphate buffered saline (PBS), fetal 
bovine serum (FBS) were purchased from Invitrogen (Grand Island, NJ). Cell titer 96 Aqueous 
One solution cell proliferation assay (MTS reagent) was purchased from Promega (Madison, 
WI).  
2.3 Methods 
2.3.1 Synthesis of mesoporous silica nanoparticles (MSN) 
 SH-, mixed SH/NH2- (50:50) and NH2-functionalized MSN were synthesized by co-
condensation of TEOS, MPTMS and APTMS using modified surfactant-templated base 
catalyzed method reported previously (Bhattarai et al., 2010). In a typical synthesis of mixed 
SH/NH2-MSN, 1.0 g of CTAB was dissolved in 480 mL of de-ionized water made basic by the 
addition of 3.5 mL of 2.0 M NaOH, and the temperature raised to 80 °C. To this solution, 5.0 mL 
TEOS was injected at a rate of ~1.0 mL/min using a syringe pump while stirring. The injection 
of TEOS was immediately followed by drop-wise addition of MPTMS (1.3 mmol) and APTES 
(1.3 mmol), to achieve a molar ratio of TEOS:MPTMS:APTES of 8.7:1:1. The dispersion was 
maintained at 80 °C for about 2 h and the final product was isolated by centrifugation. The 
isolated product was washed with excess deionized water and methanol and dried in vacuum. 
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Removal of the CTAB template was carried out by refluxing the dried product in acidic 
methanol solution (18 mL of 12 M HCl, 20 mL of methanol) overnight. The particles were 
isolated by centrifugation, washed with methanol and de-ionized water, and dried overnight 
under active vacuum in a dessicator to yield a free flowing white powder. Synthesis of SH-MSN 
and NH2-MSN was carried out using the same procedure using either 2.6 mmol of MPTMS or 
2.6 mmol APTES alone. 
2.3.2 Characterization of MSN 
The morphology and size of nanoparticles were characterized by transmission electron 
microscopy (TEM) on a JEOL 2010 Analytical Electron Microscope at 200 kV. TEM samples 
were prepared by placing a drop of a sonicated aqueous solution of MSN on a carbon-coated 
copper grid. The surface area, average pore size, cumulative pore volume, and pore size 
distributions were determined from nitrogen adsorption/desorption isotherms acquired at 77 K 
using a 30 s equilibrium interval on an ASAP 2010 Micromeritics porosimeter. The surface areas 
were computed using the Brunauer-Emmett-Teller (BET) model. The cumulative pore volumes 
and the pore size distribution was obtained from density functional theory (DFT) modeling using 
the DFT package of the Micromeritics V2.00 software over the entire range of the adsorption 
isotherm. The content of thiol and amino groups in the MSN was determined from the sulfur and 
nitrogen content in MSN measured by elemental analysis (Atlantic Microlabs Inc., Norcross, 
GA). 
2.3.3 MTX loading  
In a typical experiment, 667 µL of 4.5 mg/mL of MTX in PBS (pH 7.4) was added to 10 
mg of dry MSN. The mixture was sonicated for 30 min and kept stirring on a magnetic stirplate 
for 24 h. Then, drug loaded particles were centrifuged at 14,100 g for 10 min. After 
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centrifugation, MTX loaded MSN were vacuum dried overnight. The amount of MTX loaded in 
MSN was estimated from the MTX concentration difference in the original solution and the 
supernatant after loading in MSN. MTX concentration was determined by absorbance at 658 nm. 
Drug loading is expressed as % w/w = 100*(weight of MTX in MSN)/[(weight of MTX in 
MSN) + (weight of MSN)]. The content of MTX in MSN was also determined by 
thermogravimetric analysis (TGA) under air (Perkin-Elmer Pyris 1, 10 °C/min), subtracting the 
mass lost during analysis of empty modified MSN particles. 
2.3.4 Zeta Potential measurement  
The measurement of zeta potential of SH-MSN, SH/NH2–MSN, and NH2-MSN with and 
without MTX loading was performed using a ZetaPlus Particle Size and Zeta Potential Analyzer 
(Brookhaven Instruments) equipped with a 35-mW solid state red laser (658 nm) at 25 ºC. 
Scattered light was detected at 90°. Samples were prepared by suspending 200 µg of particles in 
2 mL PBS (pH 7.4). Zeta potential values were calculated from measured velocities using the 
Smoluchowski equation and results are expressed as the mean ± S.D. of 5 runs.  
2.3.5 In Vitro Release of MTX  
Release of MTX from MSN was analyzed by suspending a known mass of the particles 
in 2 mL of appropriate release medium (PBS, pH 7.4, or 0.2 M sodium acetate buffer, pH 4.5). 
At each pre-determined time point, MSN were centrifuged at 14,100 g for 10 min. One mL of 
supernatant was removed and replaced with 1 mL of fresh release media. The media volumes 
and drug concentrations were selected so that sink conditions were maintained during the entire 
experiment. The concentration of MTX in the supernatant was determined from absorbance at 
658 nm using a standard absorbance vs. concentration curve constructed for MTX in the 
corresponding release buffer. Because only 1 mL of the release media was removed at each time 
31 
 
 
point, the amount of released MTX was corrected for MTX remaining in the release medium 
from the previous time point. 
2.3.6 Characterization of crystalline/amorphous state of MTX in MSN 
 The crystalline state of MTX loaded in MSN was determined by differential scanning 
calorimetry (DSC) and X-ray powder diffraction (XRD). In the DSC analysis, 3-4 mg of sample 
was packed in hermetically sealed aluminum pans and heated under dry nitrogen purge using 
MDSC Model 2920 (TA instruments, New Castle, DE) equipped with a refrigerated cooling 
system. Samples were heated from 0 to 250 °C at a heating rate of 10 °C/minute. Thermograms 
were analyzed using Universal Analysis 2000 software (TA Instruments, New Castle, DE). The 
powder XRD patterns were obtained on Rigaku D/MAX-2200PC diffractometer at 40 kV and 40 
mA (Cu Kα radiation). Data were obtained from 5° to 30° (diffraction angle 2θ) at a scanning 
speed of 3°/min at room temperature. 
2.3.7 Self-quenching of MTX fluorescence in MSN 
Effect of MTX loading in MSN on self-quenching of the MTX fluorescence was studied 
by fluorescence spectroscopy using a Fluoromax-3 (Horiba Jobin Yvon Inc.). 6.9 µg/mL of 
MTX, either free or loaded in MSN, was suspended in PBS (pH 7.4). The excitation wavelength 
was set to 607 nm and emission spectra were recorded from 650 to 750 nm.  
2.3.8 Cell Culture 
Triple negative MDA-MB-231 human breast cancer cell line was a kind gift from Dr. 
Jing Li, Karmanos Cancer Institute, Detroit MI. The cells were maintained in Hyclone’s RPMI 
medium supplemented with 2.05 mM L-glutamine, 10% FBS and 1% penicillin. Cells were 
maintained in an incubator at 37 °C with 5% CO2. 
2.3.9 Cell Viability  
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Cytotoxicity of drug-loaded MSN was determined by the CellTiter 96® Aqueous Cell 
Proliferation Assay and compared with that of empty MSN. Five thousand MDA-MB-231 cells 
were seeded in a 96-well plate. One day after reaching confluence, the cytotoxicity of the 
different surface modified MSN formulations was evaluated by incubating the cells in 100 µL of 
RPMI/FBS with increasing MSN concentrations. The medium was removed after 72 h and 
replaced with a mixture of 100 µL fresh RPMI and 20 µL MTS reagent solution. The cells were 
incubated for 2 h at 37 °C. The absorbance of each well was then measured at 490 nm to 
determine cell viability. The results are expressed as mean % cell viability relative to untreated 
cells ± S.D. IC50 values were determined by Prism software using non-linear regression 
involving log (inhibitor) vs. response (three parameters) analysis of dose-response inhibition. 
2.3.10 Intracellular uptake of MTX  
Dose dependent cellular uptake of free MTX and MTX loaded in SH-MSN was 
determined by measuring cell-associated fluorescence of MTX by flow cytometry. MDA-MB-
231 cells (2.5 x 105 cells per well) were seeded in 24-well plate 12 hours before experiment. 
Cells were incubated with increasing concentration of free MTX and MTX/SH-MSN in 
RPMI/FBS for 2 hours at 37 °C. Cells were washed twice with PBS and harvested by 
trypsinization. Cells were resuspended in Hank’s buffered salt solution (HBSS) and MTX 
concentration was analyzed immediately by flow cytometry at an excitation laser wavelength of 
658 nm and using a 670 nm emission band pass filter.  Flow cytometry analysis was performed 
on a BD Biosciences LSR II instrument. Ten thousand cells were collected for each 
measurement. Cellquest software was used for data analysis. Reported fluorescence intensity 
data were corrected for cell autofluorescence using untreated cells. 
2.3.11 Intracellular release of MTX  
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Time dependent intracellular release of MTX from internalized SH-MSN particles loaded 
with MTX was determined by flow cytometry. MDA-MB-231 cells (3.8 x 105 cells per well) 
were seeded in 12-well plate 12 hours before experiment. Cells were incubated with 10 µg/ml of 
either free MTX or MTX loaded in SH-MSN in RPMI/FBS for 2 h at 37 °C. Cells were washed 
with PBS to remove any free drug and particles. The cells were then incubated for additional 2, 4 
and 6 h in RPMI/FBS and cell-associated fluorescence intensity of MTX was measured by flow 
cytometry.  
 
 
 
 
 
 
 
2.4 Results 
 This chapter reports that a simple surface functionalization of MSN can control 
crystallization, loading, release and anti-cancer activity of drug molecules. Such surface 
modification of mesoporous structure allows encapsulation of small molecular weight, charged 
drugs and release of the encapsulated cargoes in a sustained as well as controlled manner. In 
general, such modifications were limited to encapsulating unionized, hydrophobic small 
molecules based on charge-charge interaction. Our hypothesis was that controlling charge of the 
nanoparticles at given pH will improve overall drug loading, release profile and crystallization 
pattern of the encapsulated molecules. 
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Figure 1. Chemical structure of MTX 
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 To demonstrate feasibility of such surface modifications, nanoparticles were modified 
with thiol, mixed thiol/amine and amine groups and surface functionality was optimized in the 
development of successful MTX formulation with high drug loading, controlled drug release, 
amorphous form of encapsulated drug and retaining anti-cancer activity.  
2.4.1 Synthesis and characterization of surface-functionalized MSN 
Surface-functionalized MSN were synthesized by co-condensation of TEOS with the 
appropriately functionalized siloxane; MPTMS to prepare SH-MSN, APTES to prepare NH2-
MSN or a mixture of MPTMS and APTES to prepare mixed SH/NH2-MSN. The morphology 
and pore structure of the modified MSN were first analyzed by TEM (Figure 2). The TEM 
images show that all synthesized MSN had a nearly spherical shape with average diameter of 86, 
87 and 138 nm for SH-MSN, mixed SH/NH2-MSN and NH2-MSN, respectively. The presence of 
mesoporous structure in SH-MSN, mixed SH/NH2-MSN and NH2-MSN was confirmed by 
porosimetry (Figure 3). The nitrogen adsorption/desorption experiments revealed that all the 
synthesized MSN displayed type IV isotherm, a characteristic feature of mesoporous materials. 
 
 
 
 
 
 
 
Figure 2. TEM images of SH-MSN (top), 
NH2-MSN (bottom right) and mixed SH/NH2-
MSN (bottom left) (Inset: HRTEM image of 
SH-MSN). 
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The main results of the MSN characterization are summarized in Table 2. The results 
demonstrate that surface functionalization had only a limited effect on the pore size and pore 
volume of the particles. The BET surface area of the SH-MSN and SH/NH2-MSN was higher 
than surface area of the NH2-MSN particles. 
Table 2. Surface properties of SH-MSN, mixed SH/NH2-MSN and NH2-MSN. 
MSN Pore Size (Å) 
Pore Volume 
(cm3/g) 
BET S.A. 
(m2/g)a 
SH-MSN 37 0.51 776 
SH/NH2-MSN 28 0.53 754 
NH2-MSN 37 0.57 506 
 
 
a BET: Brunauer-Emmett-Teller surface area measurement 
 
 
 
 
 
 
 
 
 
 
 
The presence of thiols and amines in the MSN was confirmed by elemental analysis. The 
elemental composition of the functionalized MSN is given in Table 3. As expected, no nitrogen 
Figure 3. DFT pore size distribution of surface modified MSN. SH-MSN (top), mixed SH,NH2-
MSN (middle)  and NH2-MSN (bottom). 
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was detected in SH-MSN while no sulfur was detected in NH2-MSN. The elemental analysis 
results indicate that SH-MSN contained 1.2 mmol of SH/g of MSN, mixed SH/NH2-MSN 
contained 0.75 mmol SH/g of MSN and 0.8 mmol NH2/g of MSN, and NH2-MSN contained 1.8 
mmol NH2/g of MSN. 
                     Table 3. Elemental analysis of surface-modified MSN. 
 
 
 
 
 
 
 
 
 
 
 
 
The presence of the functional groups had a pronounced effect on the surface charge of 
MSN (Figure 4). At neutral pH, NH2-MSN had an overall positive surface charge with zeta 
potential 15.6 mV, while SH-MSN exhibited a negative surface charge with zeta potential -15 
mV. As expected, the mixed SH/NH2-MSN showed intermediate zeta potential of 5.2 mV. Zeta 
Element 
Element content (%) 
SH-MSN SH/NH2-MSN NH2-MSN 
C 4.3 6.4 8.2 
H 4.9 2.2 2.8 
N 0.0 1.1 2.5 
S 4.0 2.4 0.0 
Figure 4. Effect of surface modification and MTX loading on zeta potential of 
MSN at pH 7.4. 
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potential increased at pH 4.5 with NH2-MSN, SH-MSN, and SH/NH2-MSN showing zeta 
potential of 31.0 mV,  -2.5 mV and 16.6 mV, respectively (data not shown).  
2.4.2 MTX loading 
We have encapsulated MTX into the synthesized MSN to determine the effect of surface 
functionalization on MTX loading. The data show that modification of MSN with amino groups 
limited MTX loading to 1% w/w. In contrast, modification of MSN with thiols resulted in 
significant enhancement of MTX loading to 18% w/w (Figure 5 Left). MSN modified with both 
thiols and amines exhibited intermediate MTX loading (8% w/w). Corresponding encapsulation 
efficiencies in SH-MSN, SH/NH2-MSN and NH2-MSN particles were 60%, 27% and 3.4%, 
respectively. The differences in MTX loading among the different functionalized MSN were 
confirmed by TGA (Figure 5 Right). MTX alone decomposed fully at temperatures above 600 
°C. MSN that were not loaded with MTX showed weight loss in the range of 13 to 25% due to 
incomplete condensation of TEOS and presence of residual solvents. Comparison of the weight 
Figure 5. (Left) Effect of surface modification of MSN on MTX loading (Right) 
Thermogravimetric analysis of MSN loaded with MTX. (Inset: TGA of MTX). 
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loss of the MTX-loaded MSN with the weight loss observed for the empty particles suggested 
that the SH-MSN particles contained 21% w/w MTX, while the mixed SH/NH2-MSN particles 
contained 8% w/w MTX and the NH2-MSN particles contained only 1% w/w MTX. 
2.4.3  Characterization of MTX-loaded MSN 
MSN loaded with MTX were characterized for particle size, zeta potential, morphology, 
and physical state. TEM studies indicated that after MTX encapsulation, nanoparticles retained 
spherical morphology; however, filled pores were observed with SH-MSN (data not shown). 
Loading of the positively charged MTX increased the zeta potential of all the MSN (Figure 4). 
Upon MTX loading, the zeta potential of SH-MSN increased from -15.0 to -7 mV, while the zeta 
potential of the mixed SH/NH2-MSN increased from 5.2 to 8.1 mV. Despite low MTX loading, 
the zeta potential of NH2-MSN increased from 15.6 to 32.1 mV. In acidic conditions (pH 4.5), 
further increase in the zeta potential was observed. The zeta potential of MTX/SH-MSN was 
22.0 mV, while the zeta potential of the MTX-loaded mixed SH/NH2-MSN was 26.5 mV and the 
zeta potential of MTX/NH2-MSN was 42.8 mV.  
 
 
 
 
 
 
 
 Figure 6. Fluorescence quenching of MTX loaded in MSN 
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MTX is a fluorescent molecule with emission maximum at 685 nm. Concentration-
dependent fluorescence quenching is a well-known phenomenon that can be exploited for 
determining the release of fluorescent molecules from nanoparticles. We measured fluorescence 
of MTX loaded in the three types of functionalized MSN (Figure 6). Our result shows that the 
levels of loading achieved in SH-MSN are sufficient to achieve quenching of MTX fluorescence. 
The lower loading achieved in the two amine-containing MSN resulted in MTX fluorescence 
similar to that of the free drug. 
 
 
 
 
 
 
 
 
 
Drug crystallinity affects the rate of dissolution and release from nanoparticles. We have 
used DSC and XRD to evaluate crystalline/amorphous state of MTX loaded in MSN. The DSC 
thermograms of MTX, MTX-loaded MSN, and empty MSN are shown in Figure 7. Two 
endothermic peaks (75 and 220 °C) were observed in the sample of free MTX. The peak at 220 
°C corresponds to the melting point of dihydrochloride of MTX. The peak at 75 °C represents 
residual solvent in the commercial sample of MTX. This was confirmed by TGA by observing a 
small weight loss at that temperature. Analysis of MTX loaded in SH-MSN showed an 
Figure 7. DSC analysis of MTX-loaded MSN 
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endothermic peak at 232 °C, which was due to the phosphate buffer used in the loading protocol 
(data not shown). No signs of MTX melting point were observed in MTX-loaded SH-MSN. In 
contrast, a broad endothermic peak at 188 °C was observed in the sample of MTX loaded in 
NH2-MSN. All empty MSN and free MTX showed endothermic signals between 156-158 °C.  
 
 
 
 
 
 
 
 
Amorphous nature of MTX loaded in SH-MSN was confirmed by XRD (Figure 8). Free 
MTX showed highly crystalline nature as illustrated by the numerous peaks at 5.9, 6.2, 19.4, 
23.6, 24.4, 24.9, 25.9, and 26.3°. After encapsulation in SH-MSN no crystalline peaks of MTX 
were observed. XRD pattern of physical mixture of MTX with MTX-loaded SH-MSN showed 
distinct peaks corresponding to the pure MTX while XRD patterns of control SH-MSN, mixed 
SH/NH2-MSN and NH2-MSN were consistent with amorphous nature of the particles. XRD 
pattern of MTX loaded in mixed SH/NH2-MSN revealed non-crystalline state of MTX. NH2-
MSN loaded with MTX showed one crystalline peak at 26.3° while other MTX crystalline peaks 
were not observed indicating presence of semi-crystalline MTX in NH2-MSN.  
2.4.4  Effect of pH and surface functionality on MTX release 
Figure 8. XRD analysis of MTX-loaded MSN 
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The release behavior of MTX from the different surface functionalized MSN was 
investigated in PBS (pH 7.4) and in acidic conditions (0.2 M sodium acetate buffer, pH 4.5) to 
mimic conditions during intracellular lysosomal trafficking of the particles. Release profile of 
MTX as a function of pH and surface functionality of MSN are shown in Figure 9. The rate of 
MTX release from MSN was strongly dependent on the pH of the release media as well as 
surface modification of MSN. SH-MSN showed a much faster MTX release at pH 4.5 than pH 
7.4. Within the first 4 h ~34% MTX was released at pH 4.5 while only ~1-2% MTX was released 
at pH 7.4 from SH-MSN. In contrast, a significantly faster MTX release was observed from 
mixed SH/NH2–MSN with 75% and 90% of the drug released within 4 h at pH 7.4 and 4.5, 
respectively. MTX was released even more rapidly from NH2-MSN, with complete release 
observed within 1 h. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. Effect of pH and surface functionality on the rate of MTX release. (top) SH-
MSN, (bottom left) SH/NH2-MSN, (bottom right) NH2-MSN.  
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2.4.5  Intracellular delivery and release of MTX using SH-MSN 
Dose dependent uptake of free MTX was determined using flow cytometry after 2 h 
incubation of MDA-MB-231 cells with increasing concentrations of MTX (Figure 10 left). The 
amount of free MTX in the cells increased continuously in the entire dose range studied. The 
same assay was used to measure cell-associated fluorescence of MTX delivered by SH-MSN. 
We found significantly lower fluorescence intensity in case of MTX delivered by SH-MSN when 
compared with free MTX. Taking advantage of the self-quenching of fluorescence of MTX 
loaded in SH-MSN (Figure 6), we then followed MTX fluorescence in cells that were incubated 
for 2 h with 10 µg/mL of either free MTX or MTX in SH-MSN (Figure 10 right). The medium 
containing the drug and the nanoparticles was removed and replaced with fresh drug-free 
medium In case of free MTX, the fluorescence intensity decreased over the 6 h of observation 
indicating drug efflux from the cells. During the same time period, the fluorescence intensity in 
cells treated with MTX/SH-MSN increased almost 3-times. Initially, the intracellular 
fluorescence intensity of MTX loaded in SH-MSN was low due to quenching (Figure 6) and the 
subsequent increase in the fluorescence indicated effective intracellular release of the drug from 
the internalized particles.  
 
 
 
 
 
 Figure 10. Flow cytometry analysis to determine (left) Effect of MTX concentration 
on cell uptake and (right) Effect of post-incubation time on intracellular content of 
free MTX 
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2.4.6  Cytotoxicity of MSN 
We have determined the effect of surface functionalization on the cytotoxicity of MSN in 
MDA-MB-231 (Figure 11). Cells were incubated with increasing concentration of the different 
synthesized MSN (from 0.01 µg/ml to 100 µg/ml) and cell viability was assessed by MTS assay. 
The amine-containing particles had higher toxicity at the highest tested concentration with 83-87 
% cell viability, while SH-MSN showed a lower toxicity with 92% cell viability. 
 
 
 
 
 
 
 
2.4.7  Antiproliferative activity of MTX delivered in SH-MSN. 
Anti-proliferative activity of MTX loaded in SH-MSN was compared with free MTX in a 
human breast adenocarcinoma cells MDA-MB-231 (Figure 12). Similar activity was observed 
for both tested formulations. The concentration of SH-MSN at the highest tested MTX dose was 
79 µg/mL. At this concentration, the cell viability of cells treated with empty SH-MSN was 94% 
(Figure 11). 
Figure 11. Effect of MSN surface modification on viability of MDA-MB-231 cells (mean ± 
S.D., n=3) 
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2.5 Discussion 
 Favorable properties, such as large surface area and free volume, make MSN suitable for 
easy loading of large amounts of a wide range of drugs. The easy way of loading often results in 
rapid release of drugs and in generally poor control of the drug release from the MSN, severely 
limiting the potential of MSN in drug delivery. Additional methods of controlling the release are 
thus required, especially in case of highly soluble drugs with low affinity for silica. Numerous 
clever and sophisticated strategies have been devised to control the rate of drug release from 
MSN (Knezevic et al., 2011; Liu et al., 2010; Muhammad et al., 2011; Ruiz-Hernández et al., 
2011; Schlossbauer et al., 2010; Zhu et al., 2011). Many of the strategies, however, are not 
robust enough or compatible with physiologically relevant conditions in which drug delivery 
vectors must function. In this study, we focused on changes in surface functional groups as a 
simple way of controlling drug loading and release. We selected MTX as the drug candidate in 
our studies. MTX exerts antiproliferative activity in advanced breast cancer, acute leukemia, 
non-Hodgkin’s lymphoma and chronic myeloid leukemia by interfering with DNA synthesis 
Figure 12.  Anti-proliferative activity of free MTX and MTX loaded in SH-MSN in MDA-MB-
231 cells. (mean ± S.D., n=3) 
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through intercalation and stabilization of DNA topoisomerase II cleavable complex (Parker et al., 
2004). Non-specific organ accumulation of MTX justifies development of delivery strategies that 
can achieve improved delivery to the tumors. 
Encapsulation of drugs in MSN is governed by the interplay among drug-solvent, 
solvent-solvent, drug-silica and silica-solvent interactions. We have initially investigated MTX 
loading in organic solvents (e.g., DMSO, CH2Cl2, DMF, methanol) and mixtures of solvents 
(e.g., DMF:DMSO 1:0.1, ethanol:water 1:1, methanol:water 1:1) but none of the experiments 
resulted in drug loading above 4 % w/w. We have found that loading MTX in aqueous pH-
controlled environment provided us with substantially higher levels of loading compared with 
organic solvents. MTX is a weakly basic drug with two types of secondary amines with pKa = 
5.99 and 8.13 and its loading in MSN is thus strongly affected by surface charge of MSN and the 
pH of the loading media. We have investigated MSN modified with thiols and amines as a way 
of examining the effect of surface charge on drug loading and release. Thiol-modified MSN are 
often used in drug delivery applications because of their compatibility with standard 
bioconjugation techniques to introduce additional functionality into the particles (Lai et al., 
2003b). The SH-MSN particles maintained a strong negative charge observed also for the 
unmodified MSN and caused by the silanol and thiol surface groups. Surface modification with 
amines resulted in an overall positive charge of the particles. In order to be able to discern the 
effect of surface functionalization, we have prepared particles with similar physicochemical 
properties. 
As expected, we have found that MTX loading was strongly influenced by the pH. 
Negligible MTX loading (~1 % w/w) was observed in acidic solution (pH 2.0) regardless of the 
type of surface functionalization of MSN. MTX loading increased with increasing pH and 
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reached 18 % w/w at pH 7.4 in SH-MSN. Our results are in agreement with a recent report on 
the effect of pH on MTX loading in MSN (Ma et al., 2011). Considering that the pKa of 
mesoporous silica is ~ 7 (Ma et al., 2011), these results suggest that the pH-dependence of MTX 
loading is mainly controlled by the ionization of the surface silica in the particles. The 
importance of electrostatic interactions on silica drug loading of another weak base drug, 
doxorubicin, was reported previously (Meng et al., 2010b). 
Surface functionalization of MSN controls drug loading as well as drug release rate. 
Vallet-Regi et al. found that ibuprofen loading was higher in non-functionalized MCM-41 silica 
compared to amine modified silica (Vallet-Regí, 2006). Similar trend was observed for 
erythromycin where non-functionalized silica loading was 34% compared to 15% for 
hydrophobically modified silica (Doadrio et al., 2006). We have investigated the effect of surface 
functionalization on MTX loading using PBS (pH 7.4) as the loading medium. Increasing the 
relative content of amines in MSN resulted in drastically decreased MTX loading. This 
observation is in a good agreement with the positive role of electrostatic drug-silica interactions 
in drug loading. MTX loading increased zeta potential of all MSN, suggesting that at least some 
of the drug is adsorbed on the surface of the particles. Despite negligible overall loading, the 
largest increase of zeta potential after MTX loading was observed in NH2-MSN, suggesting 
substantial surface adsorption of the drug and thus a limited pore entry. Investigating the 
physical state of MTX in MSN by XRD and DSC showed that high loading in SH-MSN was not 
due to MTX crystallization in the pores and that MTX was present in amorphous state. 
Interestingly, MTX encapsulated in NH2-MSN showed signs of crystalinity in both DSC and 
XRD analysis. The observed decrease in melting temperature of MTX loaded in NH2-MSN is in 
accordance with the Gibbs-Thompson equation, which predicts the change of melting 
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temperature to vary linearly with the inverse of pore diameter (Ha et al., 2009). It is likely that 
electrostatic and hydrogen bond interactions of MTX with the negatively charged silica surface 
in the pores of SH-MSN inhibits crystallization of loaded MTX (Zhang et al., 2010b), while 
electrostatic repulsion between MTX and NH2-MSN does not compete with MTX-MTX 
interactions and supports crystallization. Previously, crystallization of a weakly acidic drug 
ibuprofen was observed in MSN, supporting the notion that limited interaction between drug and 
silica surface is favorable for crystallization in the pores (Riikonen et al., 2009a). 
Drug release from MSN can be varied from several hours to several days by altering pore 
size (Munoz et al., 2003), pore surface area, surface chemistry (Kapoor et al., 2009), drug 
loading (Song et al., 2011) and choice of drug molecule (Zhang et al., 2010b). Previously, 
Vallet-Regi demonstrated the feasibility of controlling the release of ibuprofen from MSN by 
functional groups of silica pore wall (Munoz et al., 2003). The same lab reported that mobility of 
ibuprofen in the porous silica confinement is dependent on surface functionalization. They found 
increased mobility for ibuprofen adsorbed on non-functionalized MCM-41 compared to amine–
functionalized particles. They attributed faster ibuprofen release rates from non-functionalized 
silica to the differences in the drug mobility (Munoz et al., 2003). Based on the observed pH-
dependence of MTX loading, we hypothesized that surface functionalization will provide a 
simple method of pH-controlled MTX release from MSN. Indeed, we observed strong pH-
dependence of MTX release in SH-MSN (Figure 10 Right) with rapid release in acidic pH and 
very slow release in neutral pH. In comparison, we observed rapid and pH-independent MTX 
release from NH2-MSN and to a large extent also from the mixed SH/NH2-MSN. These 
differences in the rate of MTX release and its dependence on the pH are due to the differences in 
the interactions of the drug with the silica matrix. Strong charge-mediated interactions of MTX 
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with negatively charged SH-MSN not only increase the drug loading as discussed earlier but also 
decrease substantially the rate of drug release. Decrease of ionization of the silica in acidic pH 
weakens the interactions and facilitates rapid drug release. In the absence of the electrostatic 
interactions in the NH2-MSN, the release rate is controlled mainly by the rate of drug dissolution. 
The strong selectivity of MTX release for acidic pH is a useful feature for drug delivery because 
it should limit the release in systemic circulation and contribute to rapid release of the drug either 
in the extracellular acidic tumor microenvironment or in the lysosomes after intracellular uptake 
(Webb et al., 2011).  
Anticancer activity of drugs encapsulated in nanoparticles is determined by the 
intracellular concentration of the free drug released from the particles. The self-quenching nature 
of the fluorescence of MTX loaded in SH-MSN represents a suitable basis for estimating the 
amount of free, i.e. non-encapsulated, MTX in the cells and the rate of intracellular MTX release 
from MSN. As shown in Figure 10 Left, the amount of free MTX present in cells immediately 
after incubation is significantly larger when using free drug than when delivering the drug with 
the particles. The situation changes significantly, however, when the intracellular amount of free 
MTX is followed after the incubation is stopped and the drug removed from the media (Figure 
10 Right). Intracellular content of MTX following incubation of cells with free drug declines 
rapidly after removal of the drug from the media. In contrast, intracellular content of free MTX 
delivered by the MSN continues to increase even after removal of the particles from the 
incubation media as the drug is being released from the internalized particles. The almost three 
fold increase in cell-associated fluorescence 6 h after incubation is a clear indication of 
intracellular release of MTX from the particles. MSN are internalized by endocytosis and 
sequestered in lysosomes (Slowing et al., 2006b). The intracellular release of MTX is then 
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triggered by the acidic pH in the lysosomes as suggested by accelerated MTX release rate in 
acidic pH. These findings suggest that MSN can deliver MTX into cancer cells and maintain 
significantly higher intracellular drug concentration than when using free drug.  
Evaluation of cytotoxicity of drug delivery carrier is as important as its drug delivery 
efficiency. In vitro toxicity of MSN is known to be highly cell-type dependent and is controlled 
by the surface area and surface functionality of the particles (Yu et al., 2011). It has been 
reported that MSN concentration below 100 µg/ml does not induces cytotoxicity in various 
cancer cells while growth inhibition is observed when concentration exceeds 200 µg/ml (Lu et 
al., 2007b; Lu J, 2010; Slowing et al., 2006b). Our results in MDA-MB-231 cells mostly 
confirmed prior findings, although we observed enhanced toxicity of the amine-containing 
nanoparticles at 100 µg/mL when compared with SH-MSN. We then assessed the anti-cancer 
efficacy of MTX delivered by SH-MSN and found similar activity as free MTX. This finding is 
not surprising. Many drug delivery systems show little benefit in cell culture where the free drug 
faces no barriers to delivery, while the particles have to overcome multiple delivery barriers. 
2.6  Conclusion 
In summary, surface functionalization of inorganic nanoparticles serves a simple tool to 
develop controlled release drug formulation. Based on these results, we conclude that thiol 
functionality is suitable for MTX formulation development which resulted in successful MSN 
based MTX formulation.  However, it has been shown that shape of such nanoparticles is 
important in improving cellular uptake and overall tumor accumulation (Arnida et al., 2011; 
Huang et al., 2009; Muro et al., 2008). To investigate the effect of shape of nanoparticles and 
their surface PEGylation, we next developed PEGylated mesoporous silica nanorods and 
optimized formulation parameters for MTX delivery (discussed in chapter 3). 
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CHAPTER 3 
SURFACE PEGYLATION OF MESOPOROUS SILCIA NANORODS (MSNR): 
IMPLICATIONS FOR LOADING, RELEASE AND DELIVERY OF MITOXANTRONE 
TO HYPOXIC TUMOR CELLS 
3.1 Introduction 
 The application of nanomaterials in drug and gene delivery has attracted much attention 
in recent decades (Farokhzad and Langer, 2009; Heffernan and Murthy, 2005). Various 
nanoparticle drug delivery systems have been developed to deliver chemotherapeutic agents to 
overcome drug resistance (Patil et al., 2009), to improve drug bio-availability (Shenoy et al., 
2005) and to achieve selective cellular targeting with diminishing chemotherapy side effects 
(Dhar et al., 2008). Interestingly, it has been shown that the shape of nanoparticles has 
significant impact on cellular uptake (Huang et al., 2009). Ghandehari et al. have shown that 
PEGylated gold nanorods had higher tumor accumulation than PEGylated gold nanospheres in 
orthotopic ovarian tumor xenograft in mice (Arnida et al., 2011). Rod shaped particles showed 
increase in the total blood circulation time compared to spherical nanoparticles, confirming that 
shape is an important characteristic of nanoparticles in drug delivery (Arnida et al., 2011; Muro 
et al., 2008). 
Inorganic materials such as mesoporous silicas offer a great potential as drug delivery 
systems due to their high drug loading, tunable pore size and pore volume, control over shape of 
the particles, easy surface modifications and an excellent biocompatibility. MSN have been used 
to deliver chemotherapeutic agents and nucleic acids in vitro (Chen et al., 2009b; Lin et al., 
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2008; Oupicky et al., 2010). MSN can encapsulate and protect hydrophobic as well as 
hydrophilic molecules and allow for controlled drug delivery (Meng et al., 2011a). In vivo 
application of MSN in cancer treatment has been investigated previously with some promising 
activity (Meng et al., 2011a; Singh et al., 2011). However colloidal instability (Graf et al., 2012) 
and hemolysis (Lin and Haynes, 2010) were major drawbacks in the development of successful 
MSN as drug delivery systems. Lu et al. addressed the problem of colloidal instability by surface 
modification of MSN with phosphonate groups to prevent aggregation of the particles by 
electrostatic stabilization (Lu et al., 2007b). Though such surface modifications improved 
colloidal stability, the issue of hemolysis was not addressed. PEGylation is a frequent strategy to 
improve colloidal stability by providing steric surface hindrance to improve particle dispersion 
and to decrease hemolysis (Lin and Haynes, 2010; Meng et al., 2011a; Zhao et al., 2011). Indeed, 
biodistribution studies of PEG-MSN showed longer blood circulation with significantly less 
phagocytosis in the liver and spleen and a decrease in the capture by the capillary vessel beds in 
the lung (He et al., 2011). Despite this, there remains a gap in our understanding of the effect of 
PEGylation on drug loading, drug release and in vitro cell drug delivery using MSN. 
Mitoxantrone (MTX) is an anthraquinoline anticancer agent that has been extensively 
studied and used in the treatment of breast and prostate cancer (Kostrzewa-Nowak et al., 2007; 
Toh and Li). MTX exerts antiproliferative activity in advanced breast cancer, acute leukemia, 
chronic myeloid leukemia and non-Hodgkin’s lymphoma by interfering with DNA synthesis 
through intercalation and stabilization of DNA topoisomerase II cleavable complex (Parker et al., 
2004). Cardiotoxicity, a severe side effect of anthraquinoline derivatives, may be overcome by 
localizing drug at the tumor site through a nanomedicine approach (Petros and DeSimone, 2010). 
Although MTX loaded solid lipid nanoparticles (Lu et al., 2006), PLGA nanoparticles and 
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liposomes (Law et al., 1996) have been developed, low loading capacity and uncontrolled MTX 
release prevented their use in preclinical applications. Shi et al. reported that mesoporous silica 
gives more control over the loading capacity and release profile of weakly basic drugs (Cui et al., 
2011; Law et al., 1996; Lu et al., 2006). In our previously published study, we described the 
effect of surface functionalization of MSN on MTX crystallization, loading and in vitro drug 
release, and demonstrated that thiol functionalized MSN is suitable for MTX formulations, 
demonstrating a classic crystalline-to-amorphous transformation, high drug loading and 
controlled MTX release (Wani et al., 2012). 
Hypoxia and acidic extracellular conditions are hallmarks of tumor microenvironments. 
Hypoxia is an adaptive trait of progressive cancers and efforts have been made to develop 
targeted therapeutics to selectively kill cancer cells (Webb et al., 2011). Poon et al. successfully 
demonstrated the localization of acidic-pH responsive nanoparticles in the hypoxic tumor 
microenvironment (Poon et al., 2011). As hypoxia and subsequent acidosis are unifying factors 
for tumor cells to acquire resistance to chemotherapy and radiation, such targeted technologies 
may be helpful to sensitize tumor cells and decrease resistance (Poon et al., 2011; Tannock, 
2001). Inspired by the pH dependent release of MTX, we hypothesized that MTX formulations 
will be more effective in hypoxic than normoxic conditions. Inherent properties of MTX such as 
increased solubility in acidic conditions and facilitated increase in the cell uptake of MTX 
justified testing of MTX delivery by MSN in hypoxic conditions. To achieve the goal, we 
investigated the effect of PEGylation on MTX release in the simulated hypoxic and normoxic 
conditions. 
In this study, we demonstrate the effect of PEGylation of mesoporous silica nanorods 
(MSNR) on loading of MTX and evaluate the in vitro release profile under simulated hypoxic 
53 
 
 
and normoxic conditions. We have synthesized PEGylated MSNR (PMSNR) and loaded MTX 
into MSNR and PMSNR using electrostatic adsorption. The effect of PEG on colloidal stability, 
hemolytic properties of MSNR, in vitro release of MTX and cell killing efficiency under 
normoxic and hypoxic conditions was studied. PEGylation decreased the overall MTX loading 
but increased the rate of MTX release. It was also found that MTX was more effective in the 
hypoxic than normoxic conditions. For the first time, we report the application of PMSNR for 
delivery of anti-cancer drugs under hypoxic conditions. 
3.2 Materials 
Tetraethylorthosilicate (TEOS), 3-mercaptopropyltrimethoxysilane (MPTMS), N-
cetyltrimethylammonium bromide (CTAB), Sodium hydroxide, hydrochloric acid, and sulfuric 
acid were purchased from Sigma-Aldrich. Mitoxantrone dihydrochloride (MTX) was purchased 
from Santa Cruz Biotechnology Inc. (Santa Cruz, CA). PEG-silane (MW 5000) was purchased 
from Laysan Bio Inc. Sheep whole blood (in sodium heparin) was purchased from Lampire 
Biological Laboratories. Roswell Park Memorial Institute medium (RPMI), phosphate buffered 
saline (PBS) (0.15M, pH 7.4) and fetal bovine serum (FBS) were purchased from Invitrogen. 
Cell titer 96 Aqueous One solution cell proliferation assay (MTS reagent) was purchased from 
Promega.  
3.3 Methods 
3.3.1 Synthesis of mesoporous silica nanorods (MSNR)  
Thiol-functionalized MSNR were synthesized by co-condensation of TEOS and MPTMS 
using a modified surfactant-templated base catalyzed method reported previously (Arnida et al., 
2011; Giri et al., 2005; Lin et al., 2008; Oupicky et al., 2010). In a typical synthesis of SH-
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MSNR, 1.0 g of CTAB was dissolved in 480 mL of de-ionized water made basic by the addition 
of 3.5 mL of 2.0 M NaOH, and the temperature was raised to 80 °C. To the rapidly stirred 
solution, 5.0 mL TEOS was injected at a rate of 1.0 mL/min using a syringe pump while stirring. 
The injection of TEOS was immediately followed by drop-wise addition of MPTMS (1.3 mmol), 
to achieve a molar ratio of TEOS: MPTMS of 8.7:1. The suspension was maintained at 80 °C for 
about 2 h and the final product was isolated by centrifugation. The isolated product was washed 
with excess deionized water and methanol and dried in vacuum. The removal of the CTAB 
template was carried out by refluxing the dried product in acidic methanol solution (18 mL of 12 
M HCl, 20 mL of methanol) overnight. The particles were isolated by centrifugation, washed 
with methanol and de-ionized water, and dried overnight under active vacuum to yield a white 
powder.  
3.3.2 Characterization of MSNR  
The morphology and size of nanoparticles were characterized by transmission electron 
microscopy (TEM) on a JEOL 2010F Analytical Electron Microscope at 200 kV. TEM samples 
were prepared by placing a drop of a sonicated aqueous suspension of MSNR on a carbon-film 
copper grid. The surface area, average pore size, cumulative pore volume, and pore size 
distributions were determined from nitrogen adsorption/desorption isotherms acquired at 77 K 
using a 30 s equilibrium interval on an ASAP 2010 Micromeritics porosimeter or a TriSTAR II 
porosimeter. The surface areas were computed using the Brunauer-Emmett-Teller (BET) model. 
The cumulative pore volumes were obtained from the BJH (Barret-Joyner-Halenda) model and 
the pore size distribution was obtained from density functional theory (DFT) modeling using the 
DFT package of the Micromeritics V2.00 software over the entire range of the adsorption 
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isotherm. The content of thiol group in the MSN was determined from the sulfur content 
measured by elemental analysis (Atlantic Microlabs Inc.). 
3.3.3 PEGylation of MSNR  
Grafting of PEG-silane on the MSNR surface was achieved by using modified method 
reported previously (Zhao et al., 2011). The MSNR surface was modified with an increasing 
amount of PEG-silane targeting MSNR:PEG ratios of 1:0.2, 1:0.4, 1:1 and 1:5 (w/w). In a typical 
experiment, 50 mg of MSNR were suspended in 2 mL of anhydrous toluene followed by  
sonication for 2-3 min. The resultant MSNR suspension was heated to 110 °C and a PEG-silane 
solution in 4 mL anhydrous toluene was added dropwise to the stirred MSNR suspension. 
Particles were stirred for 12 h and isolated by centrifugation at 13,300 rpm for 5 min, followed 
by washing with ethanol to remove unreacted PEG-silane. PEG modified MSNR were dispersed 
in 2 mL of DI water and lyophilized to obtain free flowing powder. PEGylated MSNR was 
analyzed by elemental analysis and thermogravimetric analysis (TGA). 
3.3.4 Effect of PEGylation on colloidal stability of MSNR  
Colloidal stability was characterized by dispersing 1 mg of PMSNR in 1 mL of RPMI 
containing 10% FBS followed by analysis using a Zeta Plus particle size analyzer (Brookhaven 
Instrument) for 5 h.  The intensity of the scattered light (kcps) at 90° was measured at the same 
time and plotted against time to evaluate particle sedimentation. 
3.3.5 Hemolysis assay 
Hemolytic properties of PMSNR were determined by a method reported previously 
(Vooturi et al., 2011). In a typical experiment, 2 mL of sheep whole blood was centrifuged at 
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3,000 rpm for 10 min and the supernatant containing plasma and white blood cells were 
discarded. The red blood cells (RBC) were washed with 2-3 mL of PBS until the supernatant 
became colorless to minimize background. The hemolysis assay was performed in triplicate in a 
96-well microplate using 1% Triton-X as a positive control and PBS as the negative control. 
MSNR, 1:04, 1:1 and 1:5 (targeted MSNR: PEG) were selected for the hemolysis assay based on 
colloidal stability results. In each well, 120 µL of the RBC stock was treated with increasing 
concentration of the various MSNR: PEG ratios dispersed in PBS. The final volume was 
adjusted to 150 µL by the addition of PBS. The plate was incubated at 37 °C for 1 hr. After 
incubation, the plate was centrifuged at 3,800 rpm for 5 min to collect the RBC and 20 µL of 
supernatant was diluted to 120 µL. Final diluted supernatant was analyzed by measuring 
absorbance at 414 nm to determine the release of hemoglobin. The absorbance of the positive 
control, 1% triton X, was set to 100% hemolysis. The results are expressed as mean ± S.D of 
triplicate samples. 
3.3.6 MTX loading 
In a typical experiment, 8 mg of MTX was dissolved in 4 mL of PBS (pH 7.4) and based 
on the targeted MSN:MTX weight ratio (1:0.25, 1:0.5 and 1:1) various volumes of the MTX 
solution were added to 1 mg of dry MSN. The mixture was sonicated for 30 min and then stirred 
for 24 h. The drug-loaded particles were centrifuged at 14,500 rpm for 10 min. After 
centrifugation, MTX loaded MSN were vacuum dried overnight. The amount of MTX loaded in 
MSN was estimated from the MTX concentration difference in the original solution and in the 
supernatant after loading in MSN. The MTX concentration was determined by absorbance at 658 
nm. Drug loading is expressed as % w/w = 100*(weight of MTX in MSN)/[(weight of MTX in 
MSN) + (weight of MSN)]. The results are expressed as mean ± S.D. (n=3). 
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3.3.7 Hydrodynamic radius and Zeta potential measurement 
The measurement of hydrodynamic radius and zeta potential of MSNR and PMSNR with 
and without MTX loading was performed using a ZetaPlus Particle Size and Zeta Potential 
Analyzer (Brookhaven Instruments) equipped with a 35 mW solid state red laser. Scattered light 
was detected at 90° and the temperature was set at 25 °C. Samples were prepared by suspending 
200 µg of particles in PBS (pH 7.4) at a concentration of 100 µg/ml. The mean hydrodynamic 
radius was calculated for size distribution by weight, assuming a lognormal distribution using the 
supplied algorithm and the results are expressed as mean ± S.D. of five runs. 
3.3.8 In Vitro Release of MTX 
Release of MTX from MSNR and PMSNR was analyzed by suspending a known amount 
of the particles in release medium (PBS, pH 7.4, or 0.2 M sodium acetate buffer, pH 4.5). At 
each pre-determined time point, MSN were centrifuged at 14500 rpm for 10 min. One mL of 
supernatant was removed and replaced with fresh 1 mL release medium to maintain sink 
conditions. Concentration of MTX in the supernatant was determined from absorbance at 658 nm 
using standard absorbance vs. concentration curve constructed for MTX in the corresponding 
release buffer. 
3.3.9 Cell Culture  
The triple negative MDA-MB-231 human breast-cancer cell line was a kind gift from Dr. 
Jing Li, Karmanos Cancer Institute, Detroit MI. The cells were maintained in Hyclone’s RPMI 
medium supplemented with 2.05 mM L-glutamine, 10% FBS and 1% penicillin. The estrogen 
positive MCF-7 cell line was a kind gift of Dr. Malathy Shekhar, Karmanos Cancer Institute, 
Detroit, MI. The cells were maintained in DMEM/F12 50/50 medium supplemented with L-
58 
 
 
glutamine, 5% FBS and 0.01% insulin. 10 µL of β-estradiol (10-10 M, from Sigma-Aldrich) was 
added during every culture. Cells were maintained in an incubator at 37 °C with 5% CO2 for 
normoxic condition.  For hypoxic condition, cells were maintained in an incubator installed with 
oxygen controller (ProOx model 110, BioSpherix) at 37 °C with 5% CO2 and 5% oxygen.  
3.3.10 Cell Viability  
Cytotoxicity of drug-loaded MSNR was determined by the CellTiter 96® Aqueous Cell 
Proliferation Assay. Five thousand MDA-MB-231 cells per well were seeded in a 96-well plate. 
One day after reaching confluence, the cytotoxicity of the MTX loaded PMSNR was evaluated 
by incubating the cells in 100 µL of RPMI/FBS with increasing MTX concentrations. The 
medium was removed after 72 h and replaced with a mixture of 100 µL fresh RPMI and 20µL 
MTS reagent solution. The cells were incubated for 3 h at 37 °C. The absorbance of each well 
was then measured at 490 nm to determine cell viability. The results are expressed as mean % 
cell viability relative to untreated cells ± S.D. IC50 values were determined by Prism software 
using non-linear regression involving log (inhibitor) vs. response (three parameters) analysis of 
dose-response inhibition. The results are represented as mean ± S.D. (n=3) 
3.4 Results 
3.4.1 Synthesis and characterization of PMSNR  
A representative TEM image of MSNR is shown in Figure 13 (top). The TEM image 
showed MSNR with a rod-like shape with dimensions ~120 nm x 25 nm (length x width). The 
nitrogen adsorption isotherm (Figure 13 bottom right) revealed that MSNR followed a type IV 
adsorption isotherm, typical of an MCM-41 type pore structure. The total surface area of the 
particles was determined to be (820 m2g-1). BJH analysis revealed a narrow pore size distribution 
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with an average pore size of 2.6 nm (Figure 13 bottom left). Various MSNR-PEG hybrids were 
synthesized using different MSNR: PEG ratios (w/w) 1:0.2, 1:0.4, 1:1 and 1:5. Successful 
PEGylation of MSNR surface was confirmed by elemental analysis (Table 4). The PEG content 
in PMSNR was calculated from the carbon and hydrogen content and was found to be 14.8, 24.1, 
36.2 and 37.1 (w/w %) for 1:0.2, 1:0.4, 1:1 and 1:5 MSNR: PEG ratios respectively. PEG 
content on MSNR was also confirmed by TGA analysis (Figure 14). The results also show 
increasing PEG content with increasing concentration of PEG in the reaction: 15%, 22.3%, 
29.5% and 33.2% for 1:0.2, 1:0.4, 1:1 and 1:5 ratios respectively. For the remainder of the text, 
the PMSNR will be referred to by the targeted MSNR: PEG ratios. 
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Figure 13. Physiochemical characterization of MSNR. (Top) TEM image of MSNR. (Scale Bar 
= 100 nm). (Bottom Right) Type IV adsorption isotherm measured by surface area analysis and 
(Bottom left) Pore size distribution of MSNR. 
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MSNR and PMSNR were further characterized to determine their colloidal stability, zeta 
potential and hemolytic properties. Colloidal stability was examined in deionized water and 
RPMI containing 10% FBS. Extensive aggregation of MSNR was observed in water but MSNR-
PEG (1:5) was stable during the time of study (Figure 15a). In serum -containing RPMI medium, 
light scattering showed that the MSNR colloidal stability was improved significantly; the particle 
size decreased in the first hour of incubation but stabilized afterwards, achieving a value of 550 ± 
40 nm at the end of the 5 h experiment (Figure 15c).  Increase in the PEG content in MSNR-PEG 
resulted in a decrease in average particle size and colloidally stable particles (no size change over 
the course of the experiment). Colloidal stability of MSNR-PEG was confirmed by 
sedimentation studies. The sedimentation of particles was evaluated from the combined size and 
scattering intensity data. Scattering intensity is directly proportional to the molecular weight and 
Element
Element content (%)
MSNR 1:0.2 1:0.4 1:1 1:5
C 10.6 17.1 18.8 22.9 23.2
H 2.7 3.7 3.9 4.5 4.5
S 8.6 7.3 7 6.1 6.1
0 200 400 600
0
25
50
75
100
%
 
W
ei
gh
t
Temprature  (°C)
 MSNR
 MSNR:PEG (1:0.2)
 MSNR:PEG (1:0.4)
 MSNR:PEG (1:1)
 MSNR:PEG (1:5)
  PEG-Silane
Table 4. Elemental analysis of MSNR and PEGylated MSNR (PMSNR) (1:0.2, 1:0.4, 1:1 
and 1:5 w/w MSNR: PEG). 
Figure 14. Thermogravimetric analysis of MSNR and PEGylated-MSNR. TGA was done under 
air with increase in the temperature from 0-700 °C at the rate of 10 °C/min. 
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weight concentration of the particles in solution. A change in the weight concentration with time 
due to sedimentation, or a decrease in the molecular weight due to silica hydrolysis, results in a 
decrease in the observed scattering intensity. The scattering intensity of MSNR dropped 
dramatically over the 5 hour experiment, whereas that of MSNR-PEG remained essentially 
unchanged (Figure 15b), demonstrating the role of PEG in conferring colloidal stability to 
MSNR. Sheep RBCs were used to determine hemolytic properties of MSNR and PMSNR 
(Figure 15d).  The results indicate that MSNR has dose dependent hemolytic activity while the 
presence of PEG prevented damage to RBCs.  
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Figure 15. (a) Colloidal stability of MSNR and PEG-MSNR (1:5) in water. (b) Stabilization of 
MSNR by PEGylation (1:5) confirmed by KCPS data (c) Colloidal stability of MSNR and PEG-
MSNR in 5% FBS and (d) Hemolysis study of MSNR and PEG-MSNR. 
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Zeta potential data are shown in Table 5 and Figure 16. A clear change in the zeta 
potential after PEGylation of MSNR was observed (Compare Figure 16 bottom left and Table 4 
column 1). The result showed MSNR to have a zeta potential of -11.1±0.7 mV, while the 
PEGylated particles were neutral to slightly positively charged. 
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Table 5. Zeta potential measurement of MTX loaded various MSNR-PEG counterparts. Results 
are represented as a mean and standard deviation (n=5). 
Figure 16. Effect of PEGylation of MSNR on (top) MTX loading (bottom left) zeta potential 
and (bottom right) In Vitro release of MTX. The results represented are mean ± S.D.  (n=3). 
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3.4.2 MTX Loading  
MTX loading in MSNR is a function of the electrostatic interactions between cationic 
MTX and anionic MSNR at pH 7.4. We have encapsulated MTX into MSNR as well as PMSNR 
containing different amounts of PEG in order to determine the effect of PEG content on MTX 
loading. Figure 16 (top) shows the effect of PEGylation on MTX loading in MSNR using 
increasing concentrations of MTX in the loading solution. The data showed that MTX loading in 
MSNR increased from 18% to 34% with the change in the MSNR:MTX ratio from 1:0.25 to 1:1. 
MTX loading increased in a similar way for all PMSNR but the loading decreased for all MTX 
feeding ratios with increasing PEG content in PMSNR. This suggests that MTX loading is 
hindered by the presence of PEG on the MSNR surface. We have also studied the effect of MTX 
loading on zeta potential of MSNR (Figure 16 bottom left). The results show that the zeta 
potential of particles increases as MTX content in the particles increases. The zeta potential for 
MSNR was -11.11 ± 0.68 mV, while zeta potential for 1:0.25, 1:0.5 and 1:1 MSNR-MTX ratio 
was found to be 4.5 ± 3.5mV, 8.9 ± 2.6mV and 12.3 ± 3.1 mV, respectively. However, only a 
negligible change in the zeta potential was observed after MTX loading in the different PMSNR 
(Table 4). 
3.4.3 In vitro release of MTX  
The release profile of MTX from MSNR and PMSNR (1:0.4) was investigated in PBS 
(0.15 M, pH 7.4) and in acetate buffer (0.2 M, pH 4.5) to mimic conditions during intracellular 
endo/lysosomal trafficking of particles. The effect of PEGylation on the release behavior of 
MTX is shown in Figure 16 (bottom right). The results indicate that MTX release was dependent 
on pH of the release medium as well as the degree of PEGylation of MSNR. MSNR showed a 
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much higher MTX release at pH 4.5 than pH 7.4. Within the first 6 h, about 55% of MTX was 
released from MSNR at pH 4.5, while only 1-2% was released at pH 7.4. Interestingly, 
PEGylation increased MTX release within the first 2 h to ~75% (pH = 7.4) and about 35% (pH 
=4.5).  
 
 
 
 
3.4.4 Effect of hypoxia on antiproliferative activity of MTX loaded in MSNR and PMSNR 
Cytotoxic activity of MTX-PEGylated MSNR (MTX-PMSNR) and MTX-MSNR was 
compared with free MTX in MDA-MB-231 cells and in MCF-7 cells (Figure 17). The results 
indicate that activity of MTX was decreased under normoxic conditions than under hypoxic 
conditions in both MDA-MB-231 (Figure 18) and MCF-7 (Figure 19) cells. Loading of MTX in 
MSNR resulted in a similar anticancer activity in both cell lines under normoxic conditions, 
whereas under hypoxic conditions, MTX loaded in MSNR showed higher activity in MDA-MB-
231 cells (IC50 = 0.18±0.01µg/ml, comparable to MTX alone) than in MCF-7 cells (IC50 = 
4.3±2µg/ml, less active than MTX alone). The PEGylation of MSNR had a distinct effect on the 
observed anticancer activity profiles. MTX-PMSNR was less effective than MTX-MSNR and 
free MTX under normoxia in both cell lines. Under hypoxia, MTX-PMSNR (IC50 = 0.22µg/ml) 
was as effective as MTX-MSNR (IC50 = 0.18µg/ml) and free MTX (IC50 = 0.34µg/ml) in 
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Figure 17. Effect of hypoxia on IC50 of MTX in MCF-7 cells (left) and MDA-MB-231 cells 
(right). 
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MDA-MB-231 cells. In MCF-7, MTX-PMSNR (IC50 = 5.9µg/ml) has shown lower activity 
compared with MTX-MSNR (IC50 = 4.3µg/ml) and free MTX (IC50 = 0.25µg/ml). To optimize 
the time span for effective MTX delivery, we have compared the effect of incubating MTX 
formulations for 24 and 72 h. The results showed that 24 h incubation was not sufficient for 
MTX activity under normoxic or hypoxic conditions to level off, and cell killing increased with 
72 h incubation. 
 
 
 
 
 
 
 
 
 3.5 Discussion 
Due to excellent control over particle size and shape, mesoporous silica is an attractive 
material for a wide range of applications ranging from drug delivery to theranostics (Ferrari, 
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Figure 18. Effect of hypoxia on MTX driven MDA-MB-231 cell toxicity. MTX-loaded MSNR 
toxicity in normoxic and hypoxic condition (top left and top right respectively). MTX loaded 
PEGylated MSNR toxicity in normoxic and hypoxic condition (bottom left and bottom right 
respectively. 
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2005; Park et al., 2009d). To develop MSN for controlled release applications, sophisticated 
techniques such as nanovalves (Meng et al., 2010a), pH sensitive polymer shells (Liu et al., 
2011) and various surface polymer modifications (Oupicky et al., 2010; Singh et al., 2011) have 
been applied. However, only a few studies have directly reported the effect of such techniques on 
MSN properties such as drug loading and drug release. Meng et al. reported that polymer 
attachment leaves the porous interior structure free for drug binding and hence mesoporous silica 
can be used for drug and gene delivery application (Meng et al., 2011a). Nevertheless, the same 
group reported low doxorubicin loading of 2.5-3 w/w % in PEGylated MSN. We previously 
reported that surface modification of MSN with poly(2-(dimethylamino)ethylmethacrylate) or 
poly(2-(diethylamino)ethylmethacrylate) synergistically delivered chloroquine and nucleic acids 
Figure 19. Effect of hypoxia on MTX driven MDA-MB-231 cell toxicity. MTX-loaded MSNR 
toxicity in normoxic and hypoxic condition (top left and top right respectively). MTX loaded 
PEGylated MSNR toxicity in normoxic and hypoxic condition (bottom left and right 
respectively). 
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to cancer cells with decrease in the chloroquine loading from 0.73 mg/mg in unmodified MSN to 
0.43 mg/mg in PEGylated MSN (Oupicky et al., 2010). However, Singh et al. have reported 40% 
doxorubicin loading in polymer modified MSN (Singh et al., 2011). Such discrepancies in the 
literature about the effect of surface modifications inspired us to fill this gap by (i) scrutinizing 
the effect of surface modifications on drug loading and drug release, (ii) optimizing PEG content 
for MTX loading and (iii) investigating the effect of PEGylation on MTX delivery in vitro. 
In this study, we focused on rod-shaped mesoporous silica and the effect of surface 
PEGylation on loading and release kinetics of an anticancer drug MTX. Particle shape is known 
to control biological outcomes of the delivery systems due to a change in the rate of intracellular 
uptake (Huang et al., 2009), an increase in the blood circulation time (Arnida et al., 2011) or a 
decrease in the opsonization The selection of rod shaped mesoporous silica was based on our 
preliminary in vitro studies, in which it was found that cytotoxicity of MTX loaded in MSNR 
was similar to MTX loaded in spherical MSN (data not shown). 
Non-specific organ accumulation of MTX justifies development of delivery strategies 
that can achieve improved delivery to the tumors. MTX is a weakly basic drug with two types of 
secondary amines with pKa = 5.99 and 8.13 and its loading in MSNR is thus strongly affected by 
surface charge of MSNR and the pH of the loading media. This study focused on the 
investigation of surface modifications of MSN with PEG with regards to drug loading and 
release. PEGylation of nanoparticles is widely used to modify their renal clearance, to improve 
biodistribution and to prevent opsonization by reducing the overall surface charge of 
nanoparticles (He et al., 2010b; He et al., 2011; Petros and DeSimone, 2010). However, 
PEGylation also has a dramatic impact on the surface charge. MSNR has a negative charge 
caused by the silanol and thiol surface groups. Loading of MTX into MSNR produces a positive 
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surface charge (Figure 16) which depends on the weight-to-weight (w/w) ratio between drug and 
MSNR. Thus increasing the drug concentration during loading from 1 mg/ml to 10 mg/ml 
increases w/w loading from 18 to 34%. After PEGylation, the surface charge becomes slightly 
positive to neutral (Table 5, column 1) and this decrease in the charge adversely affects loading 
capacity of MSNR for MTX. Thus, increasing the PEG content on PMSNR from 0 to 5 % 
decreases the MTX loading from 18 to ~3%. This suggests optimized PEG content is necessary 
to develop PEGylated MSNR with acceptable colloidal stability and drug loading. 
Interaction of nanoparticles with RBCs is a concern for systemic intravenous 
administration. MSN have been shown to be hemolytic in a dose dependent manner (Lin and 
Haynes, 2010; Zhao et al., 2011). It has been shown that hemolytic activity of MSN is a function 
of particle size, total surface area and the presence of silanol groups (Lin and Haynes, 2010; 
Zhao et al., 2011). PEGylation is a viable approach to counter the hemolytic nature of MSN (Lin 
and Haynes, 2010; Slowing et al., 2009). Our results confirm that MSNR are hemolytic in a dose 
dependent manner while hemolysis was prevented after PEGylation. PEGylation alters the 
charge of the particles, reduces interactions with RBCs, and hence enhances compatibility with 
blood. 
In vitro drug release from MSN has been well studied with respect to varying pore size 
(Shi et al., 2007), pore wall functional groups (Riikonen et al., 2009b), drug loading and choice 
of drug molecule (Lu et al., 2007b). Based on the pH dependent solubility of MTX, we found 
slow release of MTX at neutral pH and faster drug release at acidic pH from MSNR. Such pH 
dependence is a useful feature so that after encapsulation, we can prevent the drug release during 
in vivo circulation. Then hypoxic tumor microenvironment may help to increase localization of 
the drug at the tumor site simply based on the solubility profile of a drug molecule. Interestingly, 
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after PEGylation an increase in the rate of MTX release was observed at neutral as well as acidic 
pH. These differences in the MTX release are most likely due to changes in the electrostatic 
interactions between MTX and the silica matrix caused by PEGylation. Thus, the same 
electrostatic repulsion that makes PMSNR difficult to load with MTX, facilitates the release. 
In vitro assessment of anti-cancer agents in hypoxic conditions mimics better the tumor 
microenvironment than normoxic conditions. Hypoxia inducible factors (HIF) play an important 
role in hypoxia associated tumor development and therapeutic resistance. MTX has been shown 
to inhibit HIF-1α preferentially under hypoxic conditions (Toh and Li, 2011). In our study we 
found that MTX activity was higher in hypoxic conditions than normoxic ones in both MDA-
MB-231 and MCF-7 (Figure 18 and Figure 19). Such an increase in the activity may relate to an 
increase in the cell uptake of MTX under hypoxia. To test this hypothesis, we treated MDA-MB-
231 cells with free MTX and MTX loaded in MSNR and PMSNR. We indeed observed higher 
MTX cell uptake under hypoxia than normoxia for all formulations (Figure 17). However, we 
observed higher uptake of free MTX under both normoxic (MFI = 306) and hypoxic (MFI = 
514) conditions compared to MTX-MSNR (Normoxia MFI = 161, Hypoxia MFI = 189) and 
MTX-PMSNR (Normoxia MFI = 196, Hypoxia MFI = 299). Higher cell uptake of free drug was 
not surprising as free soluble drug faces limited barriers for delivery in vitro while with 
nanoparticle formulations, the drug has to diffuse out of the particles and the particles have to 
overcome multiple barriers. Surprisingly, despite well-established phenomenon of decreased cell 
uptake of PEGylated nanoparticles (Zhu et al., 2010), we have observed higher MTX 
accumulation in PEGylated particles compared to non-PEGylated MSNR. This agrees well with 
the results from MTX in vitro release in which higher MTX release was observed in PEGylated 
MSNR relative to MSNR at both pH 7.4 and 4.5. 
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3.6 Conclusion 
In summary, we have successfully demonstrated the effect of PEGylation of MSNR on 
loading and release of MTX. PEGylation of MSNR decreased overall drug loading but increased 
MTX release. Anticancer activity studies showed that MTX formulations were as effective as 
free MTX in hypoxic conditions but less effective in normoxic conditions. We conclude that 
further optimization of MSNR PEGylations is necessary to develop MSN as an injectable. 
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CHAPTER 4 
IS PEGYLATION OF MSN A VIABLE APPROACH TO DELIVER HYDROPHOBIC 
DRUG PACLITAXEL? 
4.1 Introduction 
 Biodegradable inorganic materials such as mesoporous silica are currently being 
investigated for the purpose of controlled release of hydrophilic drugs (Chen et al., 2009b; Cui et 
al., 2011; Wani et al., 2012), improved oral bioavailability of hydrophobic drugs (Lu et al., 
2007a; Qian and Bogner, 2012) and intracellular delivery of nucleic acids such as DNA and 
siRNA (Bhattarai et al., 2010; Chen et al., 2009b; Lin et al., 2008). High surface area, easy 
surface modifications, well controlled pore size and excellent biocompatibility persuaded 
scientists to develop mesoporous silica for drug, gene and drug-gene combinatorial delivery 
applications (Bhattarai et al., 2010; Chen et al., 2009b; Meng et al., 2011a; Singh et al., 2011). 
Paclitaxel (PTX), one of the most powerful chemotherapeutic drugs, has gained 
widespread clinical use in the treatment of breast, ovarian, non-small cell lung carcinoma, 
bladder, prostate, melanoma, and esophageal solid tumor cancers but its administration is still 
associated with significant toxicity (Sheihet et al., 2012). Paclitaxel formulations in Cremophor 
EL PTX (Taxol) has been used clinically to improve aqueous solubility of hydrophobic PTX 
(10.6 mM in water) (Mitra and Lin, 2003; ten Tije et al., 2003). Unfortunately, dose dependent 
inherent toxicity of Cremophor limits its use in the PTX formulation and there is thus a need for 
improved method of PTX solubilization. Nanotechnology holds a potential to overcome the 
problems of the PTX bioavailability and perhaps improve its therapeutic index (Farokhzad and 
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Langer, 2009). Abraxane, albumin-based nanoparticles formulation, notably improved maximum 
tolerated dose and toxicity profile of PTX compared to standard Cremophor formulation. But 
Abraxane is less effective in the treatment metastatic breast cancer and there is thus a continuing 
need for better carrier for PTX (Desai et al., 2006; Lammers et al., 2012; Sheihet et al., 2012). 
Among variety of available nanoparticles available for PTX delivery, MSN offer several 
attractive features to overcome solubility problems of hydrophobic anti-cancer drugs. High 
porous surface area and well controlled pore size of MSN can be used as a reservoir for 
solubilizing hydrophobic drugs (Lu et al., 2007a) and subsequently drugs can be released in a 
controlled as well as sustained manner. It has been shown that drug loading and release rate from 
mesoporous silica is dependent on physicochemical properties of the drug molecule (Liu et al., 
2012), surface functionalization of mesoporous structure (Cui et al., 2011; Wani et al., 2012), 
choice of solvent and partition coefficient of drug between solvent and silica matrix (Qian and 
Bogner, 2012). Surface modification of mesoporous silica by functional groups such as –COOH, 
-NH2 and –SH have been shown to modulate drug release from the silica matrix (Qian and 
Bogner, 2012; Qu et al., 2006; Riikonen et al., 2009b; Wani et al., 2012). Similarly, mesoporous 
silica surface has been modified by PEG, poly(ethyleneimine), poly(methacrylate), poly(L-
lysine) and chitosan to improve blood circulation time, to control drug release and to condense 
nucleic acid (Chen and Zhu, 2009; Hartono et al., 2012; He et al., 2010b; Meng et al., 2011a; 
Shen et al., 2011). 
Ease of pre- and post-modifications of MSN with desirable polymers gives more 
temporal control over drug release. As mentioned in the second chapter, polymer attachment 
leaves porous interior structure free for drug binding and hence, mesoporous silica can be used 
for drug and gene delivery application (Meng et al., 2011a). It has also been reported that 
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surface-modified MSN with poly(2-(dimethylamino)ethylmethacrylate) (PDMAEMA) or poly(2-
(diethylamino)ethylmethacrylate) (PDEAEMA) synergistically delivered chloroquine and 
nucleic acids to cancer cells (Bhattarai et al., 2010). But drug loading in this polymer pre-
modified MSN might be unique for particular drug and versatility of such polymer-silica hybrids 
need to be investigated with different drugs. Polymer chains swell in a good solvent to maximize 
polymer-solvent contacts while in bad solvent polymer chains stay close to each other and 
collapse forming a hard sphere (Minko, 2006). Polymers can be also present in brush and 
mushroom conformation based on grafting density (Hak et al., 2012). The extent of grafting 
density and conformation of polymeric chains in a particular solvent may be important for 
opening of porous structure and thus, important for drug loading and release. 
In this chapter, we are presenting a case of PTX formulation based on MSN with 
emphasis on the effect of PEG architecture on PTX loading. We hypothesized that architecture 
of hydrophilic PEG will affect release of PTX loaded in MSN. We have chosen six different 
PEGs to identify the effect of polymer architecture on PTX loading and release: (a) Linear-PEG 
5kDa (b) Linear-PEG 30kDa (c) Y-shaped PEG (d) loop forming PEG (SVA-PEG-SVA) (e) 4-
arm 30kDa PEG and (f) 4-arm 2kDa PEG.  
4.2 Materials  
Tetraethylorthosilicate (TEOS), 3-aminopropyltriethoxysilane (APTES), N-
cetyltrimethylammonium bromide (CTAB), Fluorescein isothiocynate (FITC), hydrochloric acid, 
and sulfuric acid were purchased from Sigma-Aldrich. Paclitaxel (PTX) was purchased from 
Santa Cruz Biotechnology Inc. (Santa Cruz, CA). Dulbecco's modified Eagle's medium 
(DMEM), phosphate buffered saline (PBS), fetal bovine serum (FBS) were purchased from 
Invitrogen. Cell titer 96 Aqueous One solution cell proliferation assay (MTS reagent) was 
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purchased from Promega. Various methyl poly(ethylene glycol)-succinimidyl valerate (mPEG-
SVA) with different architecture were purchased from Laysan Bio Inc. HPLC grade 
dichloromethane (DCM) and methanol were purchased from Sigma Aldrich. 
4.3 Methods  
4.3.1 Synthesis of FITC functionalized mesoporous silica nanoparticles (FMSN)  
FMSN was synthesized in three steps: (a) synthesis of MSN (b) preparation of 
fluorescein-APTMS conjugate and grafting of conjugate to the synthesized MSN (c) removal of 
CTAB from FMSN. 
(a) Synthesis of MSN. MSN was synthesized using modified surfactant-templated base-
catalyzed method reported previously in Chapter 1. In a typical synthesis, 1.0 g of CTAB was 
dissolved in 480 mL of de-ionized water made basic by the addition of 3.5 mL of 2.0 M NaOH, 
and the temperature raised to 80 °C. To this solution, 5.0 mL TEOS was injected at a rate of ~1.0 
mL/min using a syringe pump while stirring. The dispersion was maintained at 80 °C for about 2 
h and the final product was isolated by centrifugation. The isolated product was washed with 
excess deionized water and methanol and dried in vacuum. 
(b) Preparation of fluorescein-APTMS conjugate and grafting of conjugate on MSN. In a 
typical procedure, 2.5 ml of APTES was dissolved in 10 ml of ethanol containing 10 mg of 
fluorescein isothiocyanate (FITC). This mixture was stirred at room temperature under dark 
conditions overnight to form FITC-APTES conjugate. As-synthesized MSN was dispersed in 
100 ml of toluene and system temperature was raised to 80 °C. The FITC-conjugate solution was 
injected into the MSN dispersion dropwise using a syringe pump while stirring at a rate of ~ 1 
mL/min. After the injection, the system was left at 80 °C for about 20 h. The nanoparticles were 
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isolated by centrifugation and washed twice with methanol and then with water twice and dried 
under vacuum to yield a free flowing yellow powder. 
(c) Removal of CTAB. The dried yellow product was dispersed in 320 mL of methanol and 18 
mL of 37% HCl and refluxed overnight. The nanoparticles were isolated by centrifugation and washed 
twice with methanol and once with de-ionized water before drying under vacuum to yield a free flowing 
FMSN powder.  
4.3.2 Characterization of FMSN 
FMSN were characterized by TEM and micrometric porosimeter for particle size and 
surface area measurement respectively by a method reported previously in the chapter II (section 
2.3.2). Quantitative determination of free amines after FITC conjugation, which was required for 
further PEG modifications was measured by colorometric method reported previously (Bhattarai 
et al., 2010). The procedure consisted of two parts. In first part imine linkage was formed. In a 
typical experiment, mixture of 65 mg of FMSN, 16 mg of 4-nitrobenzaldehyde and 1 g of 
Linde’s agent was dispersed in 16 mL of anhydrous methanol. Two-three drops of glacial acetic 
acid was added to the solution. The solution was then stirred overnight under nitrogen 
atmosphere at 50 °C which resulted in the formation of imine linkage. The product was then 
isolated by centrifugation and was washed with anhydrous methanol 3 times and dried. 
In the second part, the imine linkage was hydrolyzed to generate 4-nitrobenzaldehyde. 
The dried particles were taken along with 16 mL water and 2-3 drops of glacial acetic acid. The 
contents were stirred at 40 °C overnight under N2 atm. The imine linkage was hydrolyzed and 
that resulted in the formation of 4-nitrobenzaldehyde. The compound absorbed at 269 nm and its 
concentration was monitored by UV-Vis. The concentration of the amino groups present on the 
surface of the MSN was then back calculated from the estimated concentration of 4-
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nitrobenzaldehyde. The estimated concentration of accessible amino groups on the surface of 
amine functionalized MSN was found to be 1.35x10-3 moles of NH2 / g MSN. 
4.3.3 PEGylation of FMSN 
Free amines on the FMSN surface were grafted with various mPEG-SVA by using 
modified method reported previously (Zhao et al., 2011). In a typical experiment, known amount 
of FMSN was dispersed in 2 ml of anhydrous toluene and mPEG-SVA containing solution was 
added dropwise and the mixture was heated at 110°C overnight under nitrogen. PEG-modified 
FMSN were isolated by centrifugation at 14,500 rpm for 10 min. Particles were washed with 
methanol twice to remove unreacted PEG. Subsequently, particles were dried under vacuum. 
Successful PEGylation was confirmed by TGA and elemental analysis. 
4.3.4 Colloidal stability of PEGylated FMSN 
Colloidal stability was characterized by dispersing 1 mg of various PEG-modified FMSN 
into 1 mL of RPMI medium containing 5% FBS. Particle suspension was sonicated for 30 sec 
before particle size analysis by Zeta Plus particle size analyzer (Brookhaven Instrument) for 5 h 
with 30 min interval. 
4.3.5 PTX drug loading  
In a typical drug loading experiment, known amount of PEGylated FMSN was dispersed 
in 500 µL of methanol or dichloromethane and the suspension was sonicated for 10 min to 
disperse particles. PTX solution in methanol or dichloromethane was added dropwise to FMSN 
suspension and the mixture was kept stirring overnight. After stirring, drug-loaded particles were 
centrifuged at 14,500 rpm for 10 min and supernatant was removed. Particles were dried in 
vacuum. Drug loading was determined by dispersing 1 mg of PTX-loaded FMSN or various 
77 
 
 
PEGylated FMSN in 2 mL ethanol. Particles were kept shaking overnight to extract PTX. 
Concentration of PTX was then determined by HPLC. 
4.3.6 In vitro drug release 
PTX release from FMSN was determined in PBS (0.15 M, pH 7.4) containing 0.5% (w/v) 
Tween 80 at 37 °C (Chavanpatil et al., 2006). Nanoparticle suspension (1 mg/ml, 1 ml) was 
placed in Float-A-Lyzer® dialysis tube (molecular weight cut-off 10,000 Da, Pierce), and the 
dialysis tube was immersed in 10 ml of the release buffer in a 15-ml centrifuge tube to 
maintained sink condition. The centrifuge tubes containing dialysis tubes were placed in an 
incubator shaker set at 100 rpm and 37 °C. At predetermined time intervals, 1 ml of the release 
buffer was removed from the tube and was replaced with fresh release buffer. PTX concentration 
in the buffer was determined by HPLC.  
4.3.7 HPLC analysis  
The HPLC system (Beckmann Instruments, Fullerton, CA) used consisted of a C-18 
column (4.6 mm × 25 cm) with 5 µm packing (Ascentis Express, Sigma-Aldrich, St. Louis, MO). 
The mobile phase consisted of a mixture of water and acetonitrile in the ratio of 35:65 (v/v), and 
was delivered at a flow rate of 1 ml/min. A 5 µL volume of drug sample was injected using an 
autoinjector (Model 508, Beckmann Instruments), and PTX was detected by UV absorbance at 
227 nm (System Gold 168 detector). A standard curve for PTX was prepared in ethanol and PBS 
containing 0.5% tween 80 and was used to determine PTX concentration for drug loading and 
drug release respectively. 
4.3.8 Cell Culture 
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Triple negative MDA-MB-231 human breast cancer cell line was a kind gift from Dr. 
Jing Li, Karmanos Cancer Institute, Detroit MI. The cells were maintained in Hyclone’s RPMI 
medium supplemented with 2.05 mM L-glutamine, 10% FBS and 1% penicillin. Cells were 
maintained in an incubator at 37 °C with 5% CO2. 
4.3.9  Cell uptake of FMSN 
Cellular uptake of PEG modified FMSN was determined by measuring cell-associated 
fluorescence of FITC by flow cytometry. MDA-MB-231 cells (4.0 x 105 cells per well) were 
seeded in 12-well plate 12 h before experiment. Cells were incubated with 50 µg/ml of non-
modified FMSN and various PEG-modified FMSN in RPMI/FBS for 2 h at 37 °C. Cells were 
washed twice with PBS and harvested by trypsinization. Cells were resuspended in Hank’s 
buffered salt solution (HBSS) and particle uptake was analyzed immediately by flow cytometry 
at an excitation laser wavelength of 480 nm and using a 515-545 nm emission band pass filter.  
Flow cytometry analysis was performed on a BD Biosciences LSR II instrument. Ten thousand 
cells were collected for each measurement. Cellquest software was used for data analysis. 
Reported fluorescence intensity data were corrected for cell autofluorescence using untreated 
cells. 
Similarly, FMSN uptake in MDA-MB-231 cells was confirmed by confocal microscopy. 
In a typical experiment, 50,000 cells (2 mL of RPMI/FBS medium/well) were seeded on a cover 
slip in a 6-well plate. After 24 h, cells were incubated with 500 µL of 25 µg/ml of FMSN 
suspension for 3 h to facilitate cell uptake. RPMI medium containing FMSN suspension was 
removed and cells were washed twice with warm PBS. Simultaneously, to determine sub-cellular 
distribution of FMSN, cells were incubated with RPMI containing 200nM lysotracker red and 20 
µM of hoechst 33342 to stain lysosomes and nucleus respectively. Dye containing medium was 
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removed after 10 min and cells were fixed with 0.4% paraformaldehyde for 2 h. Slides were 
removed by forceps and mounted on glass slide with a mounting media. Slides were dried 
overnight before confocal microscopy (Leica TCS SP5 laser scanning confocal microscope, 
Leica Microsystems, Buffalo Grove, IL).  
4.3.10 Cytotoxicity  
Cytotoxicity of PTX-loaded FMSN was determined by the CellTiter 96® Aqueous Cell 
Proliferation Assay. In a typical experiment, five thousand MDA-MB-231 cells were seeded in a 
96-well plate. One day after reaching confluence, the cytotoxicity of PTX and PTX loaded 
FMSN formulation was evaluated by incubating the cells in 100 µL of RPMI/FBS with 
increasing concentrations of drug and drug-loaded particles. Cells were incubated for 6 h and 
medium containing drug and drug-loaded particles were replaced with fresh RPMI medium. The 
time dependent cytotoxicity of free PTX and PTX-FMSN was determined after 24 h, 48 h and 72 
h by replacing with MTS solution (100 µL of RPMI and 20 µL of MTS reagent per well). The 
cells were incubated for 3 h at 37 °C. The absorbance of each well was then measured at 490 nm 
to determine cell viability. The results are expressed as mean % cell viability relative to untreated 
cells ± S.D. IC50 values were determined by Prism software using non-linear regression 
involving log (inhibitor) vs. response (three parameters) analysis of dose-response inhibition. 
4.4 Results and discussion 
 The main aims of this study were (a) to determine the ability of unmodified FMSN to 
load, to release and to deliver hydrophobic drug PTX and (b) to determine the effect of PEG 
architecture on colloidal stability, cell uptake and PTX loading in FMSN. To achieve these aims, 
particles were post-grafted with six PEGs. In general, polarity of solvent dictates interaction of 
hydrophobic molecules with silica matrix but drug solution has to surpass polymeric layer on 
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particles for this interaction. However, solvent should be a “good solvent” for polymer to 
facilitate swift passage of drug molecules towards porous structure to achieve successful drug 
loading. Our hypothesis was that controlling PEG architecture on the nanoparticles at a given 
solvent will subsequently improve overall drug loading and release profile. To demonstrate 
feasibility of such surface modifications, nanoparticles were modified with linear PEG (5kDa), 
linear PEG (30kDa), 4-arm PEG (2kDa), 4-arm PEG (40kDa), Y shaped PEG and SVA-PEG-
SVA (loop that forms PEG)  polymers. PEG structure was optimized in the development of 
successful PTX formulation by keeping in mind to achieve high drug loading, controlled drug 
release, high cell uptake, while retaining anti-cancer activity.  
4.4.1 Synthesis and physiochemical characterization of FMSN 
FMSN was synthesized by modification of a method reported previously (Lai et al., 
2003a; Slowing et al., 2006b; Wani et al., 2012; You et al., 2008).  A representative image of 
FMSN is shown in Figure 20a. A TEM image showed that particles were spherical with size of 
~90 nm. The observed porous structure in the FMSN was supported by the nitrogen 
adsoportion/desorption isotherm (Figure 20b). It confirmed typical type IV adsorption isotherm 
of mesoporous materials according to International Union of Pure and Applied Chemistry 
classification (IUPAC). Figure 20b shows two capillary condensations steps at P/P0 ~ 0.3 -0.4 
and P/P0 ~ 0.8 which represents typical mesoporosity. The average pore size of FMSN was 
found to be ~2.6 nm (data not shown) while BET surface area and pore volume of FMSN were 
determined to be 780 m2/g and 0.46 cm3/g, respectively. Such high surface area makes the 
particles suitable for efficient loading of chemotherapeutics in the porous structure. 
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Figure 20. Physicochemical characterization of MSN. (a) TEM image of FMSN (b) Adsorption 
isotherm of FMSN (c) Hydrodynamic size measurement and (d) Light scattering intensity vs 
time (H) for FMSN. The results are expressed as mean ± S.D. (n=3) 
  FMSN hydrodynamic size was measured in water, PBS, RPMI/FBS and Pluronic F-127 
by dynamic light scattering to determine the effect of salt, serum and surfactant on the stability 
of FMSN (Figure 20c). Hydrodynamic size was calculated from translational diffusional 
coefficient by using the Stokes-Einstein equation. The results show that FMSN were highly 
aggregated in all the studied media. Subsequently, time dependent colloidal stability in 
RPMI/FBS was also evaluated by DLS (Figure 20d). The results showed that particles were 
highly aggregated and sharp decrease in the scattering intensity confirmed colloidally unstable 
particles. Light scattering intensity sharply decreased from 600 to 100 kcps within 1 h. The 
results show that Pluronic F-127 surfactant was not sufficient to achieve collidally stable 
particles. However, it was reported that MSN can be stabilized by adsorption of serum proteins 
solvent Particle size (nm)
Water 1438.2 ± 110.2
PBS 2229.8  ± 163.0
RPMI/FBS 2958.7 ± 574.5
Pluronic F-127 1104.5 ± 56.7
100 nm
a. b.
c. d.
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(Xia et al., 2009a) and in the previous chapter III (section 3.3.4) we have also showed that MSN 
can be stabilized in the presence of FBS. Unlike those findings, however, it appears that the 
presence of FITC in the structure of FMSN makes the particles much more susceptible to 
aggregation and that serum stabilization is not effective in this case. Therefore, in order to 
achieve colloidal stability, we decided to use covalent PEGylation.  
 Efficient cell uptake of nanoparticles is necessary for intracellular delivery of 
therapeutics. It is thus important to monitor subcellular trafficking to understand localization of 
nanoparticles after cell uptake. The cell uptake of FMSN was confirmed by using confocal 
microscopy. MDA-MB-231 cells were incubated with FMSN and then cells were washed with 
PBS to remove particles that were not internalized. Routing of FMSN into the lysosomes was 
determined by staining cells with Lysotracker red and Hoechst 33342.  Lysotracker red 
specifically stains acidic endo-lysosomal organelles while Hoechst dye stains nucleus (Figure 
21). The result suggests that FMSN were located in perinuclear regions in the cells. It was 
reported that FMSN are mainly taken up into the acidic organelles and trafficked to cytoplasm 
a. b.
Figure 21. Cell uptake of FMSN by confocal microscopy. (a) Green FITC filter and (b) Overlay 
of FITC, Hoechst 33342 and lysotracker red. 
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with the help of an unspecified endolysosomal escaping effect (Huang et al., 2005). Our data 
confirm the previous findings. 
 
 
 
 
 
 
4.4.2 PTX loading and in vitro release 
 In the next study, the FMSN were loaded with PTX by soaking in drug solution in DCM 
and methanol. We found that PTX loading in FMSN was dependent on solvent selection. We 
were able to achieve higher PTX loading (~24%) from DCM compared with negligible PTX 
loading from methanol (~4%)  (Figure 22a). The difference is due to the lower polarity of DCM 
than methanol (dielectric constant 8.9 Vs 32.6, respectively) (Qian and Bogner, 2012). Charnay 
et al. and Fernandez-Nunez et al. studied range of organic solvents with different polarities for 
ibuprofen adsorption on silica matrix and observed that the more polar the solvent the greater the 
amount of ibuprofen remained in the solution and hence, less drug loading was observed 
(Charnay et al., 2004; Fernandez-Nunez et al., 2009; Qian and Bogner, 2012). These studies 
signified importance of solvent polarity for drug loading in MSN. Both studies concluded that 
this inverse relation of drug loading with solvent polarity is solely based on ibuprofen-solvent 
interactions. Preferential ibuprofen interactions with polar solvents prevent the drug from 
a. b.
Figure 22. (a) Effect of solvent on PTX loading (b) In Vitro release of PTX. Loading and 
release of PTX was determined by HPLC. 
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binding to silica. In less polar solvents, greater amount of the drug was loaded into silica due to 
preferential interactions between ibuprofen and silica. We have also extensively studied effect of 
solvent polarity on drug loading and the results will be discussed in the next chapter.  
 
After drug loading, we further explored in vitro release of PTX in PBS containing 0.5% 
Tween 80 (Figure 22b). The results show that PTX release follows biphasic release behavior in 
which initial fast release is observed (0-10 h), which is then followed by controlled release for 4 
days. It was observed that ~50% of PTX was released in the first 10 h, which we attributed to the 
release of PTX weakly adsorbed in the FMSN. Following the initial fast release, slower PTX 
release rate between 10 h and 4 days was attributed to the drugs hydrophobically interacting with 
the porous structure of silica. About 75% of PTX was released within 4 days. Similar biphasic 
Figure 23. Time dependent toxicity of PTX delivered by FMSN. 24 h (top), 48 h (bottom left) 
and 72 h (bottom right). Cytotoxicity was measured by MTS assay. The results are shown as 
mean ± S.D. (n=3). 
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release behavior has been reported previously with silica nanoparticles, liposomes (Fatouros et 
al., 2001), micelles (Park et al., 2005) as well as PLGA matrices (Wang et al., 2002). Li et al. 
reported that release of docetaxel, a hydrophilic version of PTX, from silica nanorattles was 
biphasic, the 40% was released first within 10 h followed by sustained release for 5 days (Li et 
al., 2010).  
 
 
 
 
 
 
 
 
 
4.4.3 Cytotoxicity study 
Tumor cells develop drug resistance by overexpression of drug transporters such as P-
glycoprotein (P-gp) (Milane et al., 2011b), altered expression of apoptosis associated BCL-2 
protein (Manickam et al., 2008), tumor suppressor p53 protein (Martinez-Rivera and Siddik, 
2012) and changes in the topoisomerase activity (Deffie et al., 1989). It is reported that dextran 
nanoparticles overcome P-gp mediated drug efflux by releasing and accumulating high 
concentration of drugs in the intracellular compartments (Susa et al., 2009). At the same time, 
Figure 24. IC50 values of free PTX and PTX-FMSN determined by Prism software using non-
linear regression involving log (inhibitor) Vs Response (three parameter) analysis of dose 
response inhibition. 
0.0 0.5 1.0 1.5 2.0 2.5 3.0
PTX
PTX
PTX
PTX-FMSN
PTX-FMSN
IC50 (µM) 
 72 h
 48 h
 24 h
PTX-FMSN
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PTX encapsulation in PLGA nanoparticles is susceptible to P-gp efflux in drug resistant 
NCI/ADR-RES cells and sustained inhibition of P-gp is required to achieve high therapeutic 
efficiency (Chavanpatil et al., 2006). PLGA nanoparticles encapsulating PTX showed higher cell 
killing efficiency compared to free PTX in drug sensitive MCF-7 cells. In order to understand 
PTX cytotoxicity after encapsulation in FMSN, dose dependent MDA-MB-231 cell killing was 
evaluated and compared with free PTX by MTS assay (Figure 23 and Figure 24).  
MDA-MB-231 cells were incubated with increasing concentration of free PTX and PTX-
loaded FMSN for 6 h. After incubation, drug solutions were replaced with fresh RPMI medium 
and cytotoxicity was measured after 24 h, 48 h and 72 h. The goal of this study was to 
distinguish the cytotoxic effect of free PTX after cell uptake from PTX released intracellularly 
from FMSN  The results showed that increase in the incubation time from 24 h to 72 h increased 
PTX toxicity in PTX-FMSN formulations as well as that of free PTX. It is worth noting that low 
drug doses can activate proapoptotic as well as prosurvival signaling cascades and that PTX at 
low concentrations enhances Bcl2 phosphorylation which leads to accumulation of survivin and 
X-chromosome linked inhibitor of apoptosis which leads to cell proliferation (Pushkarev et al., 
2004). We have also observed that at low doses the total number of cells increased in case of free 
PTX compared to control cells which suggests the importance of dose selection during treatment. 
Within the tested range of concentrations, both free PTX and PTX-FMSN showed time 
dependent cell inhibition. Figure 24 shows that IC50 value of free PTX after 24 h (2.9 µM) was 
41 times higher than that of PTX-FMSN (0.07 µM). After 48 h, the IC50 value decreased to 1.82 
µM for free PTX and to 0.03 µM for PTX-FMSN. Similar trend was observed after 72 h with 
IC50 value of 0.15 µM for free PTX and 0.0004 µM for PTX-FMSN. This increased activity of 
PTX-FMSN at a later time points was attributed to the sustained intracellular release of PTX 
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from the FMSN. Similarly, Yang et al. reported that activity of PTX in A549 cells increased as 
the incubation time with chitosan-PLGA nanoparticles increased from 24 h to 72 h (Yang et al., 
2009). We speculate that higher IC50 values for free PTX compared to PTX-loaded FMSN can 
be attributed to higher susceptibility of free PTX to drug efflux mechanisms. 
 
 
 
 
 
 
 
 
 
 
 
4.4.4 Effect of PEGylation on cell uptake, colloidal stability and drug loading  
Although FMSN encapsulation improved solubility of hydrophobic drugs and 
successfully delivered PTX to cancer cells, aggregation of nanoparticles still limited translation 
to preclinical in vivo application. The pharmacokinetic (PK) and biodistribution of nanoparticles 
are mainly governed by surface properties and hence, there is a need for a hydrophilic particle 
surface or surface coating for a successful intravenous administration (Hak et al., 2012). PEG is a 
Sample w/w content (%)a PEG densityb
PEG 4 arm (2kDa) 17.6 0.4
PEG 4 arm (40kDa) 14.1 0.017
Linear PEG (5kDa) 17.7 0.028
Linear PEG (30kDa) 14.4 0.137
Y shaped PEG 14.6 0.017
SVA-PEG-SVA 15.8 0.15
a.
b.
Figure 25. Characterization of PEGylated FMSN. (a) TGA profile of FMSN and various 
PEGylated FMSN (b) Table 5 represents w/w content of PEGylated FMSN determined by 
TGAa and number of PEG molecules/nm2 was calculated by formula present in the textb. 
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hydrophilic, non-toxic polymer which prevents nanoparticles aggregation by steric stabilization, 
shields overall charge of nanoparticles, prevents non-specific protein adsorption (opsonization), 
thereby delaying the removal of nanoparticles from the circulation by the ReticuloEndothelial 
System (RES) (Ryan et al., 2008).  
To reduce aggregation of nanoparticles and to improve PK and biodistribution profile, we 
modified FMSN exterior surface by PEG polymers. Our goal was to develop PTX formulation 
with PEG-FMSN that will not only improve PK profile but also create a hydrophilic barrier for 
release of hydrophobic drug during blood circulation. We selected six PEG polymers: linear PEG 
(5kDa), linear PEG (30kDa), 4-arm PEG (2kDa), 4-arm PEG (40kDa), Y shaped like PEG and 
SVA-PEG-SVA (loop that forms PEG) based on molecular weight and structure. In a synthesis 
of PEG-FMSN, PEG-SVA (NHS ester) was reacted with primary amines on the surface of 
FMSN forming stable amide linkages. The content of PEG in PFMSN was quantitatively 
determined by TGA (Figure 25a). The first observed step in the weight loss in the range of 100-
200 °C for all samples was due to the evaporation of water adsorbed in nanoparticles. The 
second step starting from 300°C was due to the loss of organic components of the studied 
sample. The results showed that FMSN were successfully modified with all selected PEGs and 
that 14-17% of PEG was present on FMSN surface.   
Considering MSN as a perfect sphere and mesopores to be perfectly aligned as cylinders, 
PEG density was calculated at the silica outer surface using the following formula (Cauda et al., 
2010):  
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DPEG = Density of PEG chains (molecule / nm2) on the exterior of MSN 
ρ = Density of silica (g/cm3) 
β = Weight of PEG chains obtained by TGA data (mg/g) 
d = Diameter of particles calculated from TEM images (nm) 
NA = Avogadro constant 
MW = Molecular weight of PEG polymer (g/mol) 
Vp = Pore volume obtained by nitrogen adsorption isotherm (cm3/g) 
10-24 = A factor added to convert m2 to nm2 
The PEG density on FMSN was found to be 0.4, 0.02, 0.03, 0.14, 0.02 and 0.15 
(molecules/nm2) for 4-arm PEG (2kDa), 4-arm PEG (40kDa), linear PEG (30kDa), linear PEG 
(5kDa), Y shaped PEG and SVA-PEG-SVA respectively (Figure 25b). Cauda et al. reported that 
short chain PEG550 covered nanoparticles surface more efficiently compared to long chain 
PEG5000 polymer due to smaller steric hindrance (Cauda et al., 2010). In our case, we found 
that PEG 4-arm (40kDa), linear PEG (30kDa) and Y shaped PEG showed low PEG coverage 
compared to PEG 4-arm (2kDa), linear PEG (5 kDa) and SVA-PEG-SVA and these differences 
in the PEG density were attributed to the greater steric hindrance and coiling. The PEG density 
on nanoparticle surface has been found to modulate blood circulation time, non-specific cellular 
uptake as well as tumor targeting potential of nanoparticles (Hak et al., 2012). Studies have 
shown that at low PEG density, PEG chains are present in mushroom conformation while at high 
PEG density PEG chains transform to brush conformation (Hansen et al., 2003; Park et al., 
2009c).  At mushroom conformation, no lateral interaction between polymeric chains of adjacent 
particles occur confirming less coverage of nanoparticles surface. Polymer chains overlap with 
each other in case of brush conformation preventing aggregation of nanoparticles and providing 
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surface protection against opsonization. However, lateral interaction between polymeric chains 
induces chain stretching outward from nanoparticles surface, increasing overall size of surface 
coating layer with increasing PEG density (Hak et al., 2012). In our case, it was important to 
correlate PEG density to the thickness of hydrophilic layer as it may control release of 
hydrophobic drug during release studies.   
In order to investigate the effect of surface PEGylation on aggregation of FMSN, 
hydrodynamic size was measured over 5 hours by DLS in RPMI containing 10% serum (Figure 
26a). The results showed that within the tested time, all PEG-FMSN were colloidally stable with 
particle sizes remaining below 500 nm. The only exception were FMSN coated with SVA-PEG-
SVA, which were stabilized at larger hydrodynamic size (~1500 nm). We speculate that due to 
two reactive ester groups, the bifunctional SVA-PEG-SVA bridged adjacent particles during 
reaction, which resulted in covalent crosslinking. At the same time, unmodified FMSN 
aggregated rapidly giving particle sizes above ~4500 nm. This confirmed that covalent 
PEGylation of FMSN is important for improvement in the colloidal stability and potentially also 
0 1 2 3 4 5
0
100
300
400
500
600
700
800
 FMSN
 4 arm 40kDa
 Linear 5kDa
 Linear 30kDa
 SVA-PEG-SVA
 Y-shaped
 4 arm 2kDa
K
CP
S
Time (h)
0 1 2 3 4 5
0
500
1000
1500
4000
6000
8000
H
yd
ro
dy
n
am
ic
 
Ra
di
u
s 
(n
m
)
Time (h)
 4 arm 2kDa
 4 arm 40kDa
 Linear 5kDa
 Linear 30kDa
 SVA-PEG-SVA
 Y-shaped
 FMSN
Figure 26. (a) Effect of PEG architecture on colloidal stability (b) Effect of PEG architecture on 
rate of sedimentation. 
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the related PK profile. Determination of sedimentation profile of nanoparticles is as important as 
the particle size measurement. Higher sedimentation is related to aggregation of nanoparticles 
which may hinder the circulation of nanoparticles and carries a risk of embolization (Kaufner et 
al., 2007). To investigate sedimentation of FMSN and P-FMSN, scattering intensity data were 
collected and plotted against time (Figure 26b). Change in the scattering intensity is dependent 
on the decrease in the molecular weight or a decrease in particle concentration due to their 
sedimentation. The results showed that unmodified FMSN aggregated and settled down at a 
higher sedimentation rate while all PEGylated FMSN were highly stable and hardly showed any 
sedimentation at the end of the 5 h study. 
 
 
 
 
 
 
 
Control cells FMSN
Linear-PEG 
(30kDa)
Linear-PEG 
(5kDa)
4-arm PEG 
(2kDa)
Linear-PEG 
(40kDa)
Y shaped PEG
MFI = 1.49 MFI = 646 
MFI = 198 MFI = 74.7 
MFI = 83.3 MFI = 17.3
MFI = 417
Figure 27. Effect of PEG architecture on MDA-MB-231 cell uptake determined by 
flow cytometry. MFI represents Mean Fluorescence Intensity. 
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Prolonged circulation time of nanoparticles is needed to enable extravasation at tumor 
sites via the enhanced permeation and retention (EPR) effect but after localization at 
pathophysiological site nanoparticles should deliver cargo efficiently to achieve higher 
therapeutic efficiency (Romberg et al., 2008). Most of the anti-cancer hydrophilic drugs, proteins 
as well as genes are not able to cross cell membrane and hence, nanoparticles encapsulation is 
required for intracellular delivery. However, polymeric surface coating interferes with the 
nanoparticle-cell interactions and limits nanoparticle uptake efficiency. It has been shown that 
PEGylation of nanoparticles decreased overall cell uptake due to loss of positive charge on 
nanoparticles (Romberg et al., 2008; Zhu et al., 2010). We investigated cell uptake of all PEG-
FMSN formulations to identify suitable PEG architecture and molecular weight. To investigate 
the effect of PEG architecture on cell uptake, various PEG-FMSN were incubated with MDA-
MB-231 cells for 3 h and cell uptake was determined by flow cytometry (Figure 27). The results 
showed that PEG architecture has significant effect on cell uptake as determined from mean 
fluorescence intensity (MFI) of FMSN. Cell uptake of unmodified FMSN was high while a 
decrease in the intensity was observed for all PEG modified FMSN. The uptake (MFI) was found 
to be 646, 83.3, 17.3, 74.7, 198, and 417 for FMSN, PEG 4 arm (2kDa), 4 arm (40kDa), linear 
PEG (5kDa), linear PEG (30kDa), and Y shaped PEG, respectively. Based on these results, we 
selected  Y shaped PEG and linear PEG (30kDa) as suitable PEG candidates for in vivo studies.  
In order to determine the effect of PEG coating on drug loading and release, PTX was 
loaded into various PEG-modified FMSN in DCM (Figure 28). The results showed that PTX 
loading is drastically reduced in the presence of PEG layer. In the studied conditions, PTX 
loading was found to be 14.5 w/w % for unmodified FMSN and between 2 to 5 w/w % for other 
studied PEG-modified FMSN. Such dramatic reduction in PTX loading was due to the blocking  
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of entry to the porous structure of FMSN by PEG. In the previous chapter, we showed that 
PEGylation also decreased loading of hydrophilic drug MTX into PEG-MSNR. However, it has 
been reported that hydrophilic drug molecules such as doxorubicin can be loaded into pre-
modified MSN with high drug loading of ~40% (Singh et al., 2011). Our study shows that 
PEGylation of FMSN reduces PTX loading and suggests that pre-modification of FMSN by PEG 
may not be a suitable approach for preparing colloidally stable MSN formulations with high 
loadings of hydrophobic drugs. 
4.5 Conclusion  
 In this chapter, we have demonstrated that FMSN can solubilize hydrophobic drug PTX 
into porous nanoconfinement and can effectively deliver PTX to cancer cells in a time dependent 
manner. FMSN surface decoration with PEG improved colloidal stability of nanoparticles but 
decreased loading of PTX into the porous structure. This is a crucial finding for the development 
of MSN as systemic drug delivery systems.  
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Figure 28. Effect of PEG architecture on PTX loading in dichloromethane. The PTX loading 
was determined by HPLC. 
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CHAPTER 5 
DEVELOPMENT OF MSN AS A COMBINATORIAL DELIVERY PLATFORM FOR 
HYDROPHILIC-HYDROPHOBIC AND HYDROPHOBIC-HYDROPHOBIC DRUG 
COMBINATIONS FOR CANCER THERAPY 
5.1 Introduction 
 Combinations of chemotherapeutic agents offer a promising therapeutic approach for the 
treatment of multi-drug resistant tumors (Farokhzad and Langer, 2009; Lee and Nan, 2012). 
Various drug combinations are widely clinically used and investigated (Lee and Nan, 2012). 
However, there is a lack of optimal strategies for combining drugs with other emerging cancer 
therapies like gene therapy. Availability of suitable delivery system is one of the reasons for the 
limited use of such combination therapies. Nanotechnology is often implemented to deliver 
chemotherapeutic combinations. Amiji and co-workers formulated PTX and curcumin co-loaded 
nanoemulsion and observed that this combination was very effective in enhancing the 
cytotoxicity in wild type and resistant cells by promoting apoptosis (Ganta and Amiji, 2009). On 
the same note, it has been reported that combining photodynamic therapy (PDT) agent, 
methylene blue with doxorubicin-loaded PLGA nanoparticles successfully overcomes drug 
resistance and improves cytotoxicity in drug-resistant tumor cells (Khdair et al., 2009). 
Nevertheless, limited encapsulation of hydrophilic drugs impedes application of widely 
investigated polymeric nanoparticles in combining hydrophilic drugs with hydrophobic ones. 
Hydrophobic core of PLGA and PLA nanoparticles often restricts hydrophilic drug loading to 
~4-5% w/w (Park et al., 2009b). In contrast, MSN hold promise for encapsulating hydrophilic 
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drugs with high drug loading, up to ~40% w/w, with enormous potential for delivery of 
hydrophilic-hydrophobic and hydrophobic-hydrophobic drug combinations (Liu et al., 2012; 
Rosenholm et al., 2010b; Singh et al., 2011). 
Advantages of MSN for drug delivery include high drug loading capacity, compatibility 
with hydrophilic-hydrophobic drugs, amorphization of loaded drugs, high surface area, tunable 
pore size, and excellent biocompatibility (Qian and Bogner, 2011; Wani et al., 2012). Due to the 
high surface-to-volume ratio with pore size around 2-10 nm, these mesoporous silica 
biomaterials can hold small molecules in the cylindrical pores which have the large internal 
surface area. Excellent chemical and mechanical stability of MSN facilitates sequential 
adsorption of drug molecules and control over drug loading in MSN is possible by tuning drug-
drug ratio (Liu et al., 2012; Rosenholm et al., 2010b). Drug molecules can be released in the later 
stage in a controlled as well as sustained manner, and release profile of drug molecules can be 
controlled by the choice of surface functionality, physicochemical properties of drugs and the 
dissolution rate of MSN (Chen et al., 2009a; Singh et al., 2011; Wani et al., 2012). Feasibility of 
loading drug molecules in the interior, porous nano-confinement and decorating MSN exterior 
surface with cationic polymers and lipids makes MSN an excellent platform in the drug-gene 
combinatorial delivery (Bhattarai et al., 2010). He and co-workers effectively utilized MSN for 
simultaneous delivery of doxorubicin and BCl-2 siRNA to multidrug resistant A2780/AD human 
ovarian cancer cells. They observed that such co-delivery effectively silenced Bcl-2 gene with 
substantial improvement in the anticancer activity of doxorubicin (Chen et al., 2009a). Such 
accumulating results proved that MSN is also a versatile system for combinatorial drug-drug and 
drug-gene delivery.  
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In this chapter, we focused on systematic optimization of co-loading of hydrophilic-
hydrophobic and hydrophobic-hydrophobic drug combinations, effect of co-loading on 
crystallization and effect of co-loading on in vitro release profile. We also report effect of co-
loading and co-mixing of anti-cancer drugs by determining cytotoxicity of breast cancer cells to 
evaluate advantage of co-loading of drugs over co-mixing. We have selected MTX as a 
hydrophilic drug and curcumin (CRM), PTX and 17-N-Allylamino-17-Demethoxygeldanamycin 
(17-AAG) as hydrophobic drugs based on first line drug combinations widely used in the breast 
cancer treatment. 
5.2 Materials  
Tetraethylorthosilicate (TEOS), 3-aminopropyltriethoxysilane (APTES), 
Mercaptopropyltrimethoxysilane (MPTMS), N-cetyltrimethylammonium bromide (CTAB), 
Fluorescein isothiocynate (FITC), hydrochloric acid, sulfuric acid and CRM were purchased 
from Sigma-Aldrich (St. Louis, MO). MTX and PTX were purchased from SantaCruz 
Biotechnology Inc. (Santa Cruz, CA). 17-AAG was purchased from LC laboratories (Woburn, 
MA). Roswell Park Memorial Institute medium (RPMI), phosphate buffered saline (PBS), fetal 
bovine serum (FBS) were purchased from Invitrogen. Cell titer 96 Aqueous One solution cell 
proliferation assay (MTS reagent) was purchased from Promega. HPLC grade dichloromethane 
(DCM) and methanol were purchased from Sigma Aldrich. Distilled water was used in the all 
experiments.  
5.3 Methods 
5.3.1 Synthesis of FITC functionalized mesoporous silica nanoparticles (FMSN)  
FMSN was synthesized in three parts: (a) Synthesis of MSN (b) Preparation of 
fluorescein-APTMS conjugate and grafting of conjugate to the synthesized MSN (c) removal of 
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CTAB from FMSN as described in the chapter 4 (section 4.3.1). FMSN was used for loading of 
PTX/17-AAG combination based on simultaneous co-loading approach; however, thiol-
functionalized MSN (SH-MSN) was used for MTX and CRM combination based on sequential 
co-loading strategy. 
5.3.2 Characterization of FMSN 
FMSN were characterized by TEM and micromeritic porosimeter for the particle size and 
surface area measurement respectively by a method reported previously in the Chapter 2 (Section 
2.3.2). Quantitative determination of free amines after FITC conjugation, which may be required 
for further modification was measured by colorometric method reported previously (Bhattarai et 
al., 2010) and as described in the Chapter 4 (Section 4.3.2). 
5.3.3 Drug loading 
5.3.3.1 Sequential loading of hydrophilic-hydrophobic drug combinations  
In a typical sequential drug loading experiment, known amount of MSN was dispersed in 
1 mL of PBS and the mixture was sonicated for 10 min to disperse particles. MTX solution was 
added dropwise to MSN suspension and mixture was kept stirring overnight. After stirring, drug-
loaded particles were centrifuged at 14,500 rpm for 10 min. Drug supernatant was removed and 
particles were vacuum dried overnight. For hydrophobic drug loading, 5 mg of CRM was 
dissolved in 2 mL of DCM, and 10 mg of MTX-loaded MSN were dispersed in the CRM 
solution followed by sonication for 30 min. MSN suspension mixture was kept stirring for 8 h. 
After stirring CRM/MTX-loaded MSN was isolated by centrifugation and vacuum drying as 
described above. Drug loading was determined by dispersing 1 mg of CRM/MTX loaded MSN 
in 2 mL ethanol. Particles were kept shaking overnight to extract CRM and MTX. Concentration 
of CRM and MTX was determined by UV-Vis spectroscopy. Drug loading was also confirmed 
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by thermogravimetric analysis (TGA) under air (Perkin-Elmer Pyris 1, 10 °C/min), subtracting 
the mass lost during analysis of empty SH-MSN particles. Similarly, individual drug loaded 
particles (MTX loaded MSN and CRM loaded MSN) were obtained according to the same 
procedure described above. 
5.3.3.2 Simultaneous loading of hydrophobic-hydrophobic drug combinations 
Simultaneous loading approach was utilized towards co-loading of PTX and 17-AAG 
instead of sequential loading due to the solubility of both drugs in the suitable solvent. In a 
typical loading experiment, known amount of FMSN was dispersed in 500 µL of DCM and 
known amount of PTX and 17-AAG was dissolved in 1 mL of DCM. Drug solution was added 
dropwise to FMSN suspension followed by sonication for 10 min. Particles were stirred 
overnight to achieve adsorption of drug molecules into the silica matrix. Drug loaded particles 
were recovered by centrifugation followed by vacuum drying as described above. Loaded drugs 
were extracted in ethanol by dispersing known amount of PTX/17-AAG loaded MSN followed 
by centrifugation. Drug concentrations in the supernatant were determined by HPLC method 
developed previously. Similarly, individual drug loaded particles (PTX loaded FMSN and 17-
AAG loaded FMSN) were obtained according to the procedure described above. 
5.3.4 Characterization of the physical state of loaded drugs 
 Crystalline state of MTX and CRM was determined by PXRD analysis as described 
previously in the Chapter 2 (Section 2.3.6).The physical state of PTX and CRM was determined 
by DSC as described previously in the Chapter 2 (Section 2.3.6). 
5.3.5 In vitro drug release 
 Effect of sequential loading of CRM in MTX/MSN on MTX release was evaluated by in 
vitro release study protocol described in Chapter 2 (Section 2.3.5). In a typical experiment, 
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known amount of MTX/MSN and CRM/MTX-MSN were dispersed in 2 mL of release medium 
(sodium acetate 0.2M, pH 4.5 and PBS, 0.2M, pH 7.4) and release of content of MTX in the 
supernatant was determined by UV-Vis spectroscopy at 658 nm.  
5.3.7 HPLC analysis  
The HPLC system used consists of a C-18 column (4.6 mm × 25 cm) with 5 µm packing 
(Beckmann Instruments, Fullerton, CA). The mobile phase consisted of a mixture of water and 
acetonitrile in the ratio of 35:65 (v/v), and was delivered at a flow rate of 1 ml/min. A 5 µL 
volume of drug sample (PTX or 17-AAG or combination of these drugs) was injected using an 
autoinjector (Model 508, Beckmann Instruments), and PTX levels were quantified by UV 
detection at 227 nm and 17-AAG levels were quantified at 254 nm (System Gold 168 detector). 
A standard curve for PTX and 17-AAG was prepared in ethanol and drug loading was 
determined based on the standard equation. 
5.3.8 Cell Culture 
Triple negative MDA-MB-231 human breast cancer cell line was a kind gift from Dr. 
Jing Li, Karmanos Cancer Institute, Detroit MI. The cells were maintained in Hyclone’s RPMI 
medium supplemented with 2.05 mM L-glutamine, 10% FBS and 1% penicillin. Cells were 
maintained in an incubator at 37 °C with 5% CO2. 
5.3.9 Cell viability study 
The CellTiter 96® Aqueous Cell Proliferation Assay determined cytotoxicity of MTX, 
CRM, PTX and 17-AAG and their loaded MSN counterparts as described previously in the 
chapter 2 (Section 2.3.9) and 4 (Section 4.3.9). In a typical experiment, five thousand MDA-MB-
231 cells were seeded in a 96-well plate. One day after reaching confluence, the cytotoxicity of 
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drugs and drugs loaded MSN formulations was evaluated by incubating the cells in 100 µL of 
RPMI/FBS with increasing concentrations. Cells were incubated for 72 h and medium containing 
drug and drug-loaded particles were replaced with MTS solution (100 µL of RPMI and 20 µL of 
MTS reagent per well). The cells were incubated for 3 h at 37 °C. The absorbance of each well 
was then measured at 490 nm to determine cell viability. The results are expressed as mean % 
cell viability relative to untreated cells ± S.D. IC50 values were determined by Prism software 
using non-linear regression involving log (inhibitor) vs. response (three parameters) analysis of 
dose-response inhibition. 
5.4 Results and discussion 
 The main goal of this study was to investigate the feasibility of MSN in the development 
of universal multi-drug delivery system for cancer therapy.  In order to develop MSN as a 
versatile and robust drug delivery platform, we investigated simultaneous and sequential loading 
strategies for combinations of hydrophobic and hydrophilic anticancer drugs. 
5.4.1 Synthesis and characterization of MSN 
 We have selected SH-MSN for MTX and CRM sequential co-loading and FMSN for 
PTX and 17-AAG simultaneous co-loading. The selection of SH-MSN for hydrophilic-
hydrophobic combination was based on the results in Chapter 2 where we showed that thiol 
functionalization is more suitable for MTX loading compared to mixed thiol/amine and amine 
functionalized MSN. In addition, inherent fluorescence of MTX negates need for the additional 
fluorescent moiety from the imaging and diagnostic point of view. However, for hydrophobic 
drugs combination, FMSN was utilized for two reasons: (1) FITC is a hydrophobic fluorescent 
marker, which helps in the imaging and (2) FITC decreases overall hydrophilicity of MSN (Yang 
et al., 2007), which may help in the loading of hydrophobic drugs through hydrophobic 
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interactions in addition to hydrogen bonding or polar interactions (Liu et al., 2012).  The results 
and discussion about the synthesis and characterization of MSN and FMSN are described in the 
Chapter 2 (Section 2.4.1) and Chapter 4 (Section 4.4), respectively. 
5.4.2 Drug loading 
5.4.2.1 Sequential loading 
 During MTX/CRM co-loading, MTX was first dissolved in the aqueous medium. 
However, care was taken in selecting pH of the loading medium as we have previously reported 
that acidic pH is not suitable for MTX loading due to ionization of MTX below pH 5.3 (Wani et 
al., 2012). The loading of MTX was controlled by the electrostatic interaction between anionic 
MSN matrix and cationic MTX at pH 7.4.  Detailed description of the MTX loading behavior in 
the MSN can be found in Chapter 2 (Section 2.5). The results showed that the adsorbed amounts 
of MTX and CRM were 176.4 ± 3.4 µg/mg and 76.3 ± 4.7 µg/mg, respectively. TGA analysis 
also confirmed the co-loading of MTX and CRM and found it to be 18% and 7%, respectively 
(Figure 29 left). 
The selection of DCM as a hydrophobic drug loading solvent was based on (i) the 
insolubility of MTX in DCM and (ii) higher loading of CRM in DCM compared to other organic 
solvents (data not shown). This difference in the solubility pattern of MTX leads us to employ 
% w/w loading
MTX CRM Total
MTX-MSN 18.3 ± 3.2 N.A. 18.3 ± 3.2
CRM-MSN N.A. 15.4  ± 1.3 15.4  ± 1.3
MTX/CRM-MSN 14.7 ± 4.2 6.8 ± 1.5 21.5 ± 5.7
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Figure 29. Sequential co-loading of MTX and CRM in SH-MSN. MTX and CRM loading was 
determined by (left) TGA and (right) UV-Vis spectroscopy. The results shown are mean ± S.D. 
(n=3). 
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sequential co-loading approach for hydrophilic-hydrophobic drugs. In fact, we have selected 
sequential loading approach due to the negligible adsorption from the simultaneous loading of 
MTX/CRM dissolved in organic solvents and co-solvents (data not shown). Instead of DCM, we 
have also tried other organic solvents such as ethanol, methanol and acetonitrile for CRM 
sequential loading but MTX was easily extracted during loading procedure in the loading 
solvent, negating advantage of high drug loading in MSN for hydrophilic drugs. We speculate 
that the interaction between MTX and used organic solvents was higher than the interaction 
MTX-MSN and MSN-organic solvent, which resulted in the higher solubility of MTX in the 
corresponding organic solvent. However, DCM provided us an excellent solvent for sequential 
hydrophilic-hydrophobic co-loading. We speculate that after MTX loading, it adsorbs in a 
monolayer fashion in the porous nano-confinement (Liu et al., 2012; Qian and Bogner, 2011) 
DCM   Acetone    CHCl3 Ethanol     DMSO
Solvent Dielectric 
constant
Dipole 
Moment 
w/w Loading 
(%)
DCM 8.9 1.18 13.1 ± 1.4
CHCl3 4.8 1.01 11.1 ± 0.3
Acetone 20.7 2.88 ND
Ethanol 24.5 1.69 ND
DMSO 46.7 3.96 ND
water 78.5 1.85 NA
Figure 30. Effect of solvent polarity on 17-AAG loading. (top) Representation of FMSN after 
17-AAG loading. Red color signifies 17-AAG loading. (bottom) Effect of polarity of solvent 
denoted by the dielectric constant and its effect on 17-AAG loading. (NA – Not applicable as 17-
AAG was not soluble in water; ND – Not determined) 
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and CRM was loaded on top of the monolayers. Electrostatic interactions played an important 
role in the MTX loading, however, we speculate that hydrophobic moieties of adsorbed MTX 
molecule played a significant role in the adsorption of CRM into MSN in addition to hydrogen 
bonding and polar interactions. In addition to MTX/CRM co-loaded MSN, MTX and CRM was 
separately loaded in the MSN and at the studied condition, w/w loading was found to be ~18% 
and ~15% for MTX and CRM, respectively (Figure 29 right). 
5.4.2.1 Simultaneous loading  
Selection of solvent is very important for simultaneous co-loading, which requires 
desirable solubility of both drugs in the loading solvent. Our previous studies confirmed that 
DCM is a suitable solvent for PTX loading (Chapter 4, Section 4.3.5) and we needed to confirm 
17-AAG loading in DCM. To investigate how selection of solvent affects loading efficiency, we 
studied the effect of polarity of solvents on 17-AAG loading (Figure 30).  Based on previous  
studies, we selected range of solvents including DMSO, ethanol, acetone, chloroform and DCM 
with differences in the polarity. We found that polarity has distinct effect on 17-AAG loading, 
with increase in the polarity decreasing 17-AAG loading. Our results suggest that in studied 
conditions chlorinated solvents such as DCM and chloroform gave highest loading between ~11-
13% compared to other studied solvents. This result ratifies that DCM is a suitable solvent for 
simultaneous co-loading of PTX and 17-AAG. Silanol groups are polar and have higher 
interaction with the polar solvent molecules compared to less polar solvents (Qian and Bogner, 
2011). This suggests that increase in the partitioning of drug molecules into the silica matrix may 
occur from less polar solvents compared to high polar ones. The Figure 31 (top) shows increase 
in the 17-AAG loading with decrease in the polarity of solvent suggested by the darker red color 
of 17-AAG. 
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After the confirmation of DCM as a common solvent, we were interested in determining 
the loading potential of FMSN used in the study. To investigate this, we increased the feeding 
amount of 17-AAG during loading experiment from 0.1 mg to 10 mg and increase in the loading 
capacity with increase in the MSN:17-AAG feeding ratio was observed (Table 6). In these 
conditions, we were able to load 432.2 µg of 17-AAG per mg of FMSN. Li and co-workers have 
formulated docetaxel formulation based on silica nanorattles and successfully achieved 480 µg 
Docetaxel/ 1 mg MSN, similar to our case. (Li et al., 2010).  
MSN:AAG 
(w:w)
Amt of AAG loaded 
(ug)/mg of MSN
w/w loading 
(%)
1:0.1 26.1 2.5
1:1 43.5 4.1
1:2 136.7 12.1
1:4 237.9 19.2
1:10 432.2 30.2
Formulation PTX loading 
(%)
17-AAG 
loading (%)
Total Loading 
(%)
PTX-FMSN 11.2 ± 0.3 NA 11.2 ± 0.3 
17-AAG-FMSN NA 12.2 ± 1.7 12.2 ± 1.7
17-AAG/PTX-
FMSN
7.9 ± 0.4 6.2 ± 2.1 14.1 ± 2.5
Table 6. Effect of feeding amount of 17-AAG on overall w/w loading. Drug loading was 
determined by HPLC. 
Table 7. Simultaneous co-loading of PTX and 17-AAG in FMSN. Loading of PTX and 17-
AAG was determined by HPLC. (Mean ± S.D. n=3) 
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In order to achieve simultaneous co-loading of PTX and 17-AAG, respective drugs were 
dissolved in DCM and adsorption of drugs into silica matrix was observed. Drug loading study 
showed that total 14% of drugs were loaded in the studied conditions and the particles contained 
7.9% of PTX and 6.2% of 17-AAG (Table 7). At the same time, we also loaded individual drugs 
(PTX and 17-AAG) into FMSN under similar conditions and drug loading was found to be 11.2 
± 0.3 and 12.2 ± 1.7% for PTX and 17-AAG, respectively. Individual feeding amount of PTX 
and 17-AAG was similar to the feeding amount of both drugs in the co-loading experiment. We 
were interested in determining the effect of co-loading in comparison with individual drug 
loading in terms of overall drug loading capacity. Kwon and co-workers studied encapsulation of 
multiple drugs (PTX, 17-AAG and rapamycin) in PEG-b-PLA micelles and observed that co-
loading of these 3 drugs increases loading capacity up to ~40% compared to ~11%, 13% and 6% 
of PTX, 17-AAG and rapamycin when individually loaded (Shin et al., 2011). The authors 
proposed that such increase in the loading capacity of PEG-b-PLA micelles was presumably due 
to intermolecular interaction among drugs in the micellar core. In our case, we didn’t observe 
increase in the total loading of multiple drugs.  
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Figure 31. PXRD analysis of sequentially co-loaded CRM and MTX in MSN. 
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5.4.3 Characterization of drug-loaded particles 
 In order to determine physical state of co-loaded drug molecules in the MSN, the 
particles were characterized by PXRD and DSC. We previously reported that after MTX loading 
into MSN, the drug was present in the amorphous form (Chapter 2, Section 2.4.3). Our XRD 
results suggest that after sequential loading of MTX and CRM, CRM was also present in the 
amorphous form, confirming strong crystalline-to-amorphous transformation of molecules in the 
porous nano-confinement of MSN (Figure 32). The presence of strong Bragg’s crystalline peaks 
of free CRM confirmed its crystalline form, however, such crystallization of CRM was not 
observed after loading into MTX-MSN.  
MSN with simultaneous co-loading of PTX and 17-AAG were characterized by DSC to 
investigate the physical state of the drug molecules. Figure 32 shows DSC analysis of PTX, 17-
AAG and the drug-loaded particles. The results show that melting point (Tm) of PTX (155.3°C), 
a crystalline signature, disappeared after loading into FMSN. Similarly, Tm of 17-AAG 
(174.1°C) was not present in the 17-AAG/FMSN formulation. We have also studied melting 
behavior of physical mixture of PTX and 17-AAG, and found two Tm at 146.4°C and 165.3°C 
for PTX and 17-AAG, respectively. After simultaneous co-loading of PTX and 17-AAG into 
FMSN, similar strong crystalline-to-amorphous transformation was observed without any signs 
of crystallinity of neither of the drugs. As reported in Chapter 2, strong Tm at 157°C from FMSN 
was assigned to the remaining CTAB in the particles (Section 2.4.3 and 2.5). Our preliminary 
study confirmed that melting point of CTAB is 171-173°C (data not shown). Decrease in the 
melting point from 172 to 157°C was attributed to the melting point depression, a classic 
phenomenon of mesoporous materials, in the porous structure as reported by the Gibbs-Thomson 
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Equation (Ha et al., 2009; Wani et al., 2012). Based on these observations, we assign that 
melting points at 183°C, 177°C and 186°C to residual CTAB present in the 17-AAG/FMSN, 
PTX/FMSN and 17-AAG/PTX-FMSN respectively. We believe that these variations in the Tm 
of CTAB were observed due to multi-steps loading process and the presence of drug molecules 
in the nano-confinement of particles; however, this hypothesis requires further support. For the 
first time, we have showed amorphization of two different molecules (hydrophilic-hydrophobic 
or hydrophobic-hydrophobic) in the porous silica structure suggesting potential of MSN in 
combinatorial drug delivery for the cancer treatment.  
 
 
 
 
 
 
 
 
 
5.4.4 In vitro release: Effect of co-loading 
 In order to understand the effect of sequential loading of CRM on MTX release, time 
dependent in vitro release study was conducted in the presence of 0.2M sodium acetate pH 4.5 
and 0.2M PBS pH 7.4. In vitro release profile of MTX is shown in the Figure 33. The results 
showed that MTX release from MSN containing both MTX and CRM had similar release profile 
as when only MTX was loaded in MSN (Section 2.4.4 and 2.5). Higher release was again 
FMSN
FMSN-17-AAG
17-AAG
PTX
PTX-17-AAG
FMSN-PTX
FMSN-PTX,17-AAG
Figure 32. DSC of free PTX and 17-AAG and drug loaded FMSN counterparts 
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observed in acidic pH (~43% MTX at pH 4.5 in the first 2 h) and minimal release was observed 
at pH 7.4 (~4% MTX in the first 2 h).  Interestingly, the presence of CRM in the co-loaded 
particles only affected the initial rate of MTX release (inset Figure 33). It was observed that 
~43% of MTX was released at pH 4.5 during first 2 h in the absence of CRM; however, ~23% of 
MTX release was observed in presence of CRM. These results are in accordance with the study 
conducted by He and co-workers who observed initial decrease in the rate of doxorubicin release 
after PTX loading into MSN (Liu et al., 2012). Interestingly, the opposite effect of CRM on the 
overall release of MTX was observed at pH 4.5. The particles released ~85% of MTX in the 
presence of CRM vs.  ~63% in the absence of CRM. Only a minimal effect of CRM co-loading 
was observed on MTX release at pH 7.4. Due to the poor aqueous solubility of CRM, surfactants 
such as tween 80 are normally used to achieve desirable water solubility required for conducting 
drug release experiments (Shahani and Panyam, 2011). In general, 10-15% of Tween 80 is 
required to achieve sink condition (Shahani et al., 2010). Because the presence of such high 
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Figure 33. Effect of CRM co-loading on release of MTX. Sodium acetate (0.2M, pH 4.5 ) and 
PBS (0.2M, pH 7.4) was used for the release studies and concentration of MTX in the 
supernatant was determined by UV-Vis spectroscopy at 658 nm. (Inset: Initial rate of MTX in 
presence of CRM) 
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amount of Tween 80 affected the pH dependance of MTX release, we could only investigate 
MTX release.  
Drug release data can be fitted to several different kinetic models: zero-order, first-order, 
Hixson-Crowell, Higuchi, or Korsmeyer-Peppas models (Costa and Sousa Lobo, 2001; Huang 
and Brazel, 2001; Korsmeyer et al., 1983). The zero-order release describes systems where drug 
release rate is independent of its concentration. The first-order rate systems are concentration 
dependent. The Hixon-Crowell model is useful in systems where there is a change in the surface 
area and diameter of the drug delivery system, with progressive dissolution of the formulation as 
a function of time (Costa and Sousa Lobo, 2001). The Higuchi model is based on Fickian 
diffusion and emphasizes the release of drugs from an insoluble matrix as a square root of a 
time-dependent process (Costa and Sousa Lobo, 2001). The Kormeyer-Peppas model represents 
a comprehensive approach to describe and explain the kinetics of drug release from hydrophilic 
matrices (Korsmeyer et al., 1983). This model is expected to be valid up-to ~ 60% of drug 
release and release data should be restricted to that range. Based on the well-known dissolution 
Figure 34. The Koresmeyer-Peppas plots. The diffusion exponent (n) determines the mechanism 
of drug release. n < 0.45 represents simple Fickian diffusion, 0.45 < n < 0.89 represents non-
Fickian diffusion.  
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profile of hydrophilic MSN, we selected Korsmeyer-Peppas model to understand MTX release 
kinetics from the silica matrix. The same approach has been reported previously in case of drug 
release from MSN (Liu et al., 2012). The Korsmeyer-Peppas equation is as follows: 


 =   

 
Where,   and   are the cumulative mass of drug released at a time t and infinite time, 
respectively;   is the kinetic constant of the drug-carrier system; and n is an exponent that 
characterizes the mechanism of drug release. The Korsmeyer-Peppas plots for our data are 
shown in Figure 34. The results indicate that up to 60% release, MTX release at pH 4.5 could be 
fitted into the Korsmeyer-Peppas model with good linearity and exponent n was lower than 0.45. 
The MTX release data at pH 7.4 could not be fitted as well with R2 = 0.85 and 0.94 in case of  
release from MTX-MSN and from MTX+CRM-MSN, respectively. According to the 
Korsmeyer-Peppas model, the diffusional exponent (n) less than 0.45 corresponds to a simple 
diffusion-controlled Fickian process that involves diffusion of solvent molecules into the pores 
of MSN to dissolve drug molecules and the diffusion of the dissolved drug out of the mesopores. 
We propose that lower solubility of MTX at pH 7.4 results in the decrease of the drug diffusion 
out of MSN pores, which negatively affects the linearity of the fit. 
It has been reported that MSN undergoes dissolution as a function of time while keeping 
the initial geometrical form unchanged (Bhattarai et al., 2010; Rosenholm et al., 2010b). To 
support this notion mathematically, we investigated the use of Hixon-Crowell model for our drug 
release data. This model assumes unchanged geometrical shape but a decrease in the surface area 
and diameter of the matrix over time. This model also assumes that the release rate is limited by 
the drug particles dissolution rate and not by the diffusion of drug molecules through the matrix 
(Costa and Sousa Lobo, 2001). The Hixon-Crowell equation is as follows: 
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Where, 	


  and 

   indicate the initial amount of drug and cumulative amount of drug release 
at time t respectively;   is a Hixon-Crowell release constant and t is time in hours. Our results 
indicate that MTX release from MTX-MSN and MTX+CRM-MSN at pH 4.5 did not fit well (R2 
= 0.82 and 0.51, respectively) confirming that the release of MTX from MSN is a diffusional 
process. It is well known that the release of hydrophilic drugs incorporated in matrix is a 
diffusion controlled process while for poorly soluble drugs, the erosion of the matrix is the main 
controlling element of the release (Costa and Sousa Lobo, 2001; Huang and Brazel, 2001). 
The in vitro release profile of simultaneously co-loaded PTX/17-AAG-FMSN was not 
conducted due to the previously described practical limitations associated with the aqueous 
solubility of PTX and 17-AAG.    
5.4.5 In vitro cytotoxicity 
 Various combinations of anti-cancer drugs have been clinically proven to give excellent 
tumor regression. It is important to understand whether combination therapies can benefit from 
drug delivery using nanoparticles (Lee and Nan, 2012). It may be possible that two drugs with 
clinically established synergistic effect without nanoparticles formulation will change the activity 
profile after encapsulation in nanoparticles. In such scenario, screening of such combinations 
using nanoparticles is a need of the hour and keeping this in mind, we investigated the in vitro 
cell viability study of FMSN loaded with PTX/17-AAG combination. Our goal was to answer 
the basic question of combinatorial drug delivery: What is the benefit of co-loading two drugs in 
nanoparticles over co-mixing of individually loaded nanoparticles?  This fundamental question 
remains under-investigated in the field of combinatorial drug delivery. 
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As shown in Figure 35, IC50 values of free drugs PTX and 17-AAG in MDA-MB-231 
human breast cancer cells were 70 ± 3.4 and 19.7 ± 4.2 nM, respectively. These results agree 
well with previously reported values (Roforth and Tan, 2008; Turturro et al., 2007). For PTX/17-
AAG drug combination, the IC50 was found to be 18.5 ± 5.7 nM. However, IC50 values of PTX 
and 17-AAG loaded in the FMSN were found to be 17 ± 2.3 and 33.4 ± 5.1 nM, respectively. 
Interestingly, IC50 values for co-loaded and co-mixed PTX/17-AAG formulations were 68 ± 2.7 
and 11 ± 6.3 nM, respectively. This suggests that co-mixing of PTX/FMSN and 17-AAG/FMSN 
is more effective than co-loading of both drugs in the same particle. Our results are in 
accordance with findings of Kwon and co-workers who studied anti-cancer activity of 2-in-1 
combination of PTX and 17-AAG in PEG-b-PLA micelles and found that IC50 value of micellar 
formulation of drug combos (118 ± 1.8 nM) was higher compared to a mixture of free drugs (30 
± 4 nm) (Shin et al., 2011). On the other hand, Sasikheran and co-workers designed nanocells 
comprised of a nanoparticle within PEGylated-lipid envelope in which the outer lipid layer first 
released anti-angiogenesis agent which was then followed by a release of a chemotherapeutic 
agent from the nanoparticle (Sengupta et al., 2005). The authors evaluated the effect of physical 
Figure 35. Effect of co-loading and co-mixing of PTX and 17-AAG formulations on MDA-MB-
231 cell viability. The results shown are mean ± S.D. (n=3) 
Formulation IC50 (nM)
PTX solution 70 ± 3.4
17AAG solution 19.7 ± 4.2 
PTX/17-AAG solution 44.5 ± 5.7
PTX/FMSN 17 ± 2.3 
17-AAG/FMSN 33.4 ± 5.1
Co-loaded PTX/17-
AAG/FMSN
68 ± 2.7 
Co-mixing of PTX/FMSN & 
17-AAG/FMSN
11 ± 6.3
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mixing of combretastatin A4 and doxorubicin over co-loading of these drugs and found that this 
combination was more effective in the co-loaded form compared to the physical mixture. They 
also reported that such temporal release of two drugs within tumor resulted in improved 
therapeutic index with reduced toxicity. These accumulating results suggest that there is a need 
to develop and optimize such combinations based on nanoparticles to treat tumor progression. 
The results also show that benefits of drug co-delivery using nanoparticles are strongly 
dependent on the specific drug combinations and disease indications. 
5.5 Conclusion 
 In summary, we have developed a strategy to co-load hydrophilic-hydrophobic and 
hydrophobic-hydrophobic drug combinations in MSN. We suggest that MSN can serve as a 
universal delivery platform for rapid screening of potential benefits of co-delivery of a broad 
range of drug-drug combinations. MTX/CRM and PTX/17-AAG combinations were successfully 
co-loaded into MSN using either  sequential or simultaneous drug loading strategy. Drug loading 
was found to be more than 200 µg/mg and 140 µg/mg for MTX/CRM and PTX/17-AAG 
combinations, respectively. Physical characterization of drug-loaded MSN by XRD and DSC 
confirmed that drug combinations were in the amorphous form. The drug release data confirmed 
that release of MTX was based on Fickian diffusion at pH 4.5, regardless of the presence or 
absence of CRM. In contrast, limited release was observed at pH 7.4 due to pH dependent 
solubility of MTX. Anticancer activity of PTX/17-AAG combination suggested that co-mixing 
of individually loaded nanoparticles is more effective than co-loading both drugs into the same 
nanoparticles. Our results show versatility and robustness of MSN as a drug delivery system in 
terms of delivering combinations of chemotherapeutic agents.  
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 Future studies will further evaluate MSN formulations of hydrophilic-hydrophobic drug 
combinations. This research thus sets a strong foundation for future in vivo tumor suppression 
studies based on multi-drug delivery approach. In addition, MSN formulations can be developed 
to improve oral bioavailability of hydrophobic drug combinations considering its ability to 
improve aqueous solubility. Thus, these results would facilitate therapeutic applications of MSN 
as a combinatorial platform for multidrug chemotherapy.  
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Our long term goal is to develop a versatile and robust injectable carrier based on 
Mesoporous Silica Nanoparticles (MSN) for drug/drug combination therapies. The objective of 
my dissertation was to optimize surface functionality, particle shape and methods of colloidal 
stabilization of mesoporous silica by PEG for delivery of drug/drug combinations. This was 
achieved by pursuing the following three aims: 
1. Optimize surface functionality of MSN for high drug loading and controlled release 
2. Investigate the effect of particle shape and PEGylation on drug delivery in hypoxic tumor cells 
3. Develop MSN capable of delivering drug/drug combinations 
To investigate the effect of surface functionalization of MSN on crystallization, loading, 
release and activity of mitoxantrone (MTX), we synthesized thiol (SH), mixed thiol/amine 
(SH/NH2) and amine (NH2) functionalized MSN by sol-gel process. We observed that NH2 
modification of MSN has limited MTX loading. In contrast, modifications of MSN with SH 
resulted in significant enhancement of MTX loading. MTX loading was controlled by pH of the 
loading media and surface charge of MSN. The SH-MSN particles maintained a strong negative 
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charge due to silanol and thiol surface groups while amine modified MSN resulted in an overall 
positive charge. Differences in the loading were due to decrease in the electrostatic interaction 
between MTX and MSN. Based on the observed pH-dependence of MTX loading, we 
hypothesized that surface functionalization will provide a simple method of pH controlled MTX 
release from MSN. Indeed, we observed strong pH-dependence of MTX release in SHMSN with 
rapid release in acidic pH and very slow release in neutral pH. In comparison, MTX was released 
rapidly from NH2-MSN regardless of the pH. Similar to loading, the differences in the release 
behavior are due to differences in interactions of the drug with the silica matrix. Another 
important aspect of mesoporous silica is amorphization or crystalline-to-amorphous 
transformation of drugs in the porous nanoconfinement. We found strong effect of surface 
functionalization of MSN on crystallization of MTX. In SH-MSN particles, MTX was found to 
be in the amorphous form while semi-crystalline MTX was present in the NH2-MSN. This is a 
very interesting feature as surface functionalization serves as a simple tool to allow control over 
MTX loading, its crystallization and release profile.  
After optimizing surface functionality, we investigated the effect of surface PEGylation 
and particle shape on loading and release profile of MTX in hypoxic tumor cells. We synthesized 
thiol functionalized mesoporous silica nanorods (MSNR) and stabilized them with different 
amount of covalently attached PEG. The focus on rod-shaped particles was based on studies 
showing beneficial properties of nanorods for increased blood circulation and tumor 
accumulation compared with spherical particles. We found that PEGylation decreased zeta 
potential of MSNR with improved colloidal stability but reduced overall MTX loading as a 
function of PEG content. PEGylation also increased the rate of MTX release compared to release 
from non PEGylated MSNR. We found that MTX had better anticancer activity in hypoxic than 
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normoxic conditions, while no clear effect of particle shape was observed. Flow cytometry study 
confirmed that increased activity of MTX formulations in hypoxic conditions was due to 
increased cell uptake and retention of the drug in the cells.  
To achieve our long-term goal of developing a robust and versatile drug delivery carrier, 
we investigated feasibility of co-loading of hydrophilic hydrophobic and hydrophobic-
hydrophobic drug combinations in MSN. We found that loading of hydrophobic molecules such 
as PTX and 17-AAG depends on the polarity of solvent, with less polar solvents improving drug 
loading. We have successfully co-loaded PTX and 17-AAG into the same particles. We observed 
that PEGylation decreases loading of hydrophobic molecules. We hypothesize that this decrease 
in the drug loading was due to blocking of access to the pores. This is a new observation and we 
are currently investigating alternative ways to stabilize co-loaded MSN without compromising 
drug loading. 
Inorganic particles like MSN offer an interesting alternative to organic drug delivery 
systems like polymeric nanoparticles, micelles and liposomes due to high drug loading capacity 
and biocompatibility. We demonstrated the effect of surface functionalization and PEGylation of 
MSN on crystallization, drug loading and release, and colloidal stability. We showed effective 
delivery of MTX using PEGylated MSN in hypoxic conditions that has significant promise in the 
treatment of clinically important triple negative as well as estrogen positive breast cancers. We 
also showed MSN are capable of delivering drug-drug combinations for cancer treatment. 
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